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1. Introduction 
 
1.1 Objective 
The goal for thesis was to evaluate genetic polymorphisms, which are 
associated with pain perception in human patients suffering from symptomatic knee 
osteoarthritis (question 1). A second goal of this study was to find out if specific 
genetic markers that correlate with treatment response in regard to different intra-
articular treatment modalities in mid stage knee osteoarthritis (KOA) (question 2).  
 
1.2 Hypothesis  
1.2.1 Question 1:  
 Specific single nucleotide polymorphisms (SNPs) exist that are associated 
with pain report in patients suffering from symptomatic mid-stage knee osteoarthritis. 
 
1.2.2 Question 2: 
 Certain SNPs show a correlation with treatment response of three different 
therapeutic intra-articular injections -autologous conditioned serum (ACS), hyaluronic 
acid (HA) and Saline as placebo (PL)- in patients suffering from symptomatic mid-
stage knee osteoarthritis. 
 
1.3 Osteoarthritis 
1.3.1 Epidemiology  
Osteoarthritis (OA) is a widespread degenerative articular disease, which can 
affect many joints –most common ones are knee-, hip-, facet joints and joints in 
hands, more common the distal interphalangeal joints (DIPJs) (Hunter & Felson, 
2006). Known risk factors are trauma, the presence of constant micro trauma in form 
of sports –especially squatting (Heidari, 2011)- and obesity (Hunter & Felson, 2006) 
as well as genetics (Thakur, Dawes, & McMahon, 2013) beside other known factors. 
The following box shows a brief summary of relevant facts concerning epidemiology 
of OA.  
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• WHO estimated a worldwide prevalence for symptomatic OA of 9.6% of men 
and 18.0% of women > 60y in 2015 (WHO, 2015) 
• Prevalence of radiographic evidence of knee OA (KOA) in adults with the age 
of >60 years was 37% in the US; Prevalence of symptomatic KOA in adults 
>60 years with radiographic indices for KOA was 12% in the US (Dillon, 
Rasch, Gu, & Hirsch, 2006) 
• Prevalence of OA lies around 21.1-22.3% in women and 17.9% in men in 
Germany in 2010. >50% of affected joints were knee OA for both gender 
(Fuchs, 2013; Robert-Koch-Institut, 2010). Robert-Koch-Institut (RKI) data 
has been collected through a non-standardized self-register.  
• Risk factors: female gender (Cross et al., 2014), obesity for bilateral KOA 
(Hunter, 2009) (Heidari, 2011; Hochberg et al., 1995), age (Heidari, 2011), 
previous knee injuries especially for unilateral KOA 3.86 fold (Blagojevic, 
Jinks, Jeffery, & Jordan, 2010), genetic factors1(WHO, 2013), estrogen 
deficiency (Sun, Sturmer, Gunther, & Brenner, 1997)2, low intake of Vitamin C 
and D questionable  
• Most affected joint being knee joint with consequence of rising global burden 
to treat KOA (Cross et al., 2014) 
 
1.3.2 Pathophysiology 
Furthermore instability, misaligned axis, dysfunction of congruence present 
predispositions for osteoarthritis (Eaton, 2004; Heidari, 2011). Osteoarthritis occurs 
when our protective cartilage tissue is worn down and subchondral bone is exposed 
(Hunter, 2009; WHO, 2013).  
It can be said that osteoarthritis manifests especially in load-bearing joints –where a 
great strength of contraction of periarticular muscles is shown-, rather than the 
weight-bearing joints (Kenneth D. Brandt, 2010). This may give an attempt to explain 
why DIPJs are infested amongst other typical joints like knee and hip joint. (Brandt 
KD, 2010). Osteoarthritis is a complex multifactorial disease with a strong 
inflammatory component where many components interact (de Rezende, de 
Campos, & Pailo, 2013; Man & Mologhianu, 2014; Pelletier, Martel-Pelletier, & 
                                                 
1 Example for genetic factors influencing OA: point mutation 519 from arginine to cysteine in 
the fibrillar alpha II chain. Genetic mutations causing changes in matric of articular cartilage 
(Arita M., 2002) 
2 the progression of KOA accelerates after the age of 50 in women, suggesting that lower 
levels of estrogen may have an effect upon progression in KOA (Kenneth D. Brandt, 2010) 
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Abramson, 2001; Robinson et al., 2016). Articular cartilage proteolytic degradation 
occurs due to differed homeostasis in chondrocytes in favor of pro inflammatory 
cytokines and matrix metalloproteinases (MMPs) and reduced synthesis of collagen 
type 2 leading to an initial increment in thickness of cartilage, followed by clefts, tears 
and wearing off (Man & Mologhianu, 2014). Other components in the interplay are 
metabolism and hypomineralization of subchondral bone, as well as a hyperplastic 
synovia with presence of proinflammatory cells, such as lymphocytes and 
synoviocytes (macrophage-like cells) releasing proinflammatory cytokines (like IL-1, 
IL-6, TNF), angiogenic factors (VEGF) and MMPs leading to further inflammation 
and degradation. It is being discussed whether the synovitis is a consequence or part 
of pathogenesis of OA. Meniscal damage also plays a role in the pathogenesis. 
Overall, a variety of joint tissue and a interaction between mechanical and biological 
factors are suggested to be involved in the underlying pathology of OA (Man & 
Mologhianu, 2014).  
The state of a chronic low-grade inflammation results in peripheral sensitization as 
well as in central sensitization on spinal level as well as in the brain stem, 
hypothalamus and cortex. Peripheral afferent endings ‘Silent-nociceptors’ (type III 
and IV nerve fibres) are activated by inflammation or tissue-damaging stimuli (Grigg, 
Schaible, & Schmidt, 1986) (Schaible & Schmidt, 1985, 1988). Mechanisms, such as 
PGE activation and long-term gene induction of nerve growth factor (NGF), tumor 
necrotic factor (TNF), lower the excitatory level of nociceptors, hence lowering the 
pain threshold (Kidd, 2012; Kidd, Photiou, & Inglis, 2004). Via neuronal activation of 
TrkA receptors, NGF causes a sensitization of nociceptive articular afferences, 
reducing threshold for pain (Kidd, 2012). An amplified response –through NMDA-
receptor activation and proinflammatory gene induction-, an increment in receptive 
field and a modulation of descending inhibitory pathways are mechanisms of central 
sensitization at spinal level (Kidd et al., 2004) 
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• Degenerative progress with a low-grade inflammation being a key feature 
(Heidari, 2011; Robinson et al., 2016)  
• Load-bearing joints are especially afflicted (DIPJs) (Kenneth D. Brandt, 2010) 
• Initial thickening of cartilage due to increased water content as a 
consequence of a damaged collagen network. With progression of KOA 
cartilage thins down due to a reduced production of proteoglycans, leading to 
vertical clefts. When fibrillated clefts and horizontal tears join, cartilage is 
worn down and subchondral bone becomes exposed (Heidari, 2011; Kenneth 
D. Brandt, 2010; Man & Mologhianu, 2014).  
• Multiple complex mechanisms lead to peripheral nociceptive sensitization and 
central sensitization (Grigg et al., 1986; Kidd, 2012; Kidd et al., 2004) 
 
1.3.3 Clinical features and Diagnostics 
 Symptomatic OA is defined by the attendance of chronic pain and functional 
disability (Thakur et al., 2013). The major symptom in KOA is joint pain, which 
aggravates under weight-bearing movement during and after (Hunter & Felson, 
2006). Along to the slowly progressive pain are a loss of function so that the range of 
movement within this joint may be reduced, tenderness or stiffness –especially in the 
mornings-(Hunter & Felson, 2006; WHO, 2013). A periarticular muscular arthropathy 
due to pain-related immobility, as well as swelling and increased warmth above the 
affected joint can be signs of KOA (Brandt KD, 2010). Fever, anemia and weight loss 
are not initial symptoms in KOA and would rather point towards a rheumatoid 
problem (Hunter & Felson, 2006). Blood tests and joint fluid analysis can be used to 
exclude other causes for articular pain, such as local infections or rheumatoid 
arthritis. A proper anamnestic talk and clinical examination filtering for symptoms 
described above can enable a doctor to point towards a diagnose KOA. A 
questionnaire named painDETECT can be used to evaluate whether a neuropathic 
component exists within the pain disorder of patients with chronic pain (Freynhagen, 
Baron, Gockel, & Tolle, 2006).  
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Diagnostic tools 
• Detailed anamnesis, including characteristics of pain, medical history, family 
history, comorbidities such as metabolic diseases, rheumatic diseases 
• Questionnaires- eg. WOMAC, painDETECT- used to standardize subjective 
pain report  
• Physical examination looking for swelling, deformation, axial alignment, pain 
evoking pressure points, restrictions in range of movement (RoM) of a joint, 
Heberden´s and/or Bouchard nodes, examination of the hip –since diseases 
affecting the hip can cause knee pain as well-, neurological status –to 
exclude radiculopathies- 
• Sonographic imaging: popliteal Baker cyst, synovia, edema periarticular 
• Blood test: inflammatory signs, CRP, IL6, Leukocytes, Rheuma factors, anti-
CCP-Antibody 
• Synovial fluid analysis: inflammatory signs by evaluating appearance, 
viscosity, cell count, concentration of glucose.  
• Radiological imaging, see below 
 
1.3.4 Radiological Criteria of KOA  
Criteria to diagnose Osteoarthritis are joint space narrowing, osteophytes, 
subchondral sclerosis and subchondral cysts, which can be observed on X-ray-
imaging (Kellgren JH, 1957). Above mentioned Symptoms of osteoarthritis often 
develop gradually over time. Other signs of osteoarthritis may be a grating sensation 
under pressure due to joint space narrowing or being able to manually feel 
osteophytes (http://www.mayoclinic.org/diseases-
conditions/osteoarthritis/basics/symptoms/con-20014749).  
X-ray imaging is the standard diagnostic procedure following clinical 
examination (WHO, 2013). The Kellgren-Lawrence-Scale can be used to classify 
osteoarthritis into four grades –criteria being joint space narrowing, osteophytes, 
subchondral sclerosis and subchondral cysts (J. H. Kellgren, 1957). MRI is used in 
more complex circumstances and does not count as a standard procedure. 
It is well known that a disassociation between radiographic presence of KOA 
and pain report exists (Hunter & Felson, 2006; Lethbridge-Cejku et al., 1995). 
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Grade Severity of KOA radiographic findings 
0 None No features of OA 
I Doubtful Minute osteophyte, 
doubtful significance 
II Minimal definite osteophyte, 
unimpaired joint space 
III Moderate Moderate diminution of 
joint space 
IV Severe Joint space greatly 
impaired, with sclerosis of 
subchondral bone 
 
Table 1: Kellgren-Lawrence-Classification scales radiographic structural damage of OA and 
allows a standardized assessment of the severity of KOA on x-rays. (J. H. Kellgren, 1957) 
 
1.3.5 Therapeutic overview 
A step-up approach of therapeutic opportunities, beginning with conservative 
possibilities, over interventional options to surgical options, is currently state of the 
art.  
Conservative therapy includes pain medication with Acetaminophen, NSAIDs 
against the inflammatory component (see review), physical therapy to control 
overweight, orthopedic-technical support such as shoe inserts or psychological 
therapy to control chronic pain (Wehling P., 2016). Reducing weight (kg) in obese 
patients plays a center role in non-pharmacological therapeutic strategies due to a 
correlation between high levels of leptin and risk of KOA (Christensen, Bartels, 
Astrup, & Bliddal, 2007; Dumond et al., 2003); further details of underlying 
pathologies of the association is outlined in chapter 2.4.  
Interventional therapies are little invasive options for treatment. Local cortisone 
injections can be applied into the joint to reduce inflammation and pain if NSAIDs and 
oral pain medication fail to achieve a reasonable pain reduction. Hyaluronic acid is a 
natural component of joint fluid and is allowed as treatment for osteoarthritis, 
functioning as a lubricant when also injected intra-articularly. Arthroscopic cartilage-
surgery such as abrasio and drilling follow the principle of refreshing the cartilage via 
micro trauma. A more complex possibility is the mosaic procedure, where a small 
degenerative area is punched out and replaced with healthy autologous bone-
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cartilage tissue from immediate surroundings within the treated joint, which are not 
exposed to high pressure (http://praxisklinik-heinsberg.de/wordpress/op-
infos/arthroskopie-des-kniegelenks/knorpelchirurgie). Interventional modalities 
include intra-articular injections as well as arthroscopic cartilage-surgery with the 
goals of reducing inflammation, achieving an analgesic effect and slowing down 
progression of OA.  
A surgical alternative if conservative and interventional therapeutic 
approaches have failed is arthroplasty, joint replacement surgery with either metal or 
plastic substances, most commonly done for hip- and kneeOA. Disadvantages to this 
are that with an invasive procedure the risk of developing postoperative 
complications such as infection and loosening of the implanted the prosthesis, blood 
clots followed by thromboembolic incidences, vascular- and nerve injury and other 
general postoperative complications increases. Challenging is also a follow up 
surgery if the artificial joint is outworn or needs replacement. Complications may lead 
to arthrodesis as the ultimo ratio.  
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conservative approach 
• Nonpharmacological: 
education, Moderate 
Physical exercise, 
Weight loss in case 
of obesity 
• Biomechanical: 
Thermal modalities: 
acute pain → cold; 
chronic pain → 
warm, Wedged 
insoles in case of 
genu vara/valga, 
Elastic bandages, 
immobilization 
splints, Acupuncture 
• Pharmacological: 
Analgesics 
(Acetaminophen, 
Opioids) NSAIDs, 
disease-modifying 
drugs  
surgical/operative 
approach 
• Arthroscopic: 
lavage, 
debridement, 
micro fracturing, 
mosaic techniques 
• Unicompartimental 
knee arthroplasty 
• Total joint 
arthroplasty  
• arthrodesis 
intra-articular approach 
• 8 FDA-approved 
Corticosteroids 
• 7 FDA-approved 
Hyaluronates 
• various analgesics 
• TNF-Antagonists 
(Infliximab, 
Etanercept, 
Adalimumab) with 
an intra-joint half-
live of 2-4h 
• IL1-Antagonists 
Anakinra3,  
• Blood-derived: 
PRP, ACS 
• Stem cell therapy 
 
 
Data derived from Wehling et al (Wehling P., 2016). For a detailed overview including brief 
description & indication please see review on “How does surgery compare with advanced 
intra-articular therapies in KOA: current thoughts”. The table is supposed to give a brief 
overview on the great spectrum of possible treatment options. 
 
  
                                                 
3 An indication for TNF-antagonist as well as for Anakinra is the posttraumatic prevention of 
KOA –eg after rupture of the anterior cruciate ligament- (Kraus et al., 2012).  
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1.3.6 Intra-articular therapeutic modalities in knee osteoarthritis  
One of the advantages of intra-articular injection is the improvement of directly 
delivering a drug to the cartilage(Evans, Kraus, & Setton, 2014).  Drug efficacy of 
reaching cartilage is greater than when a drug is applied systemically; a systemically 
administered drug (eg. p.o. or i.v.) can then only reach cartilage over the subchondral 
vasculation and afterwards diffusion from synovial fluid into cartilage.  
Interventional modalities include intra-articular injections of a variety of 
substances, such as cortisone, acting anti-inflammatory, and HA, functioning as a 
natural lubricant. However, there are controversial opinions, meta-analyses and 
guidelines (example given OARSI guideline 2014 (McAlindon et al., 2014), AAOS 
recommendation 2013 (Brown, 2013)) on how effective intra-articular injections with 
hyaluronic acid are. For an extended review on intra-articular review see Evans et al 
(Evans et al., 2014). Further, systemic side effects are eluded when a drug is applied 
intra-articular. 
A difficulty that comes up in intra-articular therapies is the short dwell time of 
drugs within a joint, which is a problem in chronic pain conditions. The exit of a drug 
depends upon its molecular size; micro molecular structures exit via capillaries, 
whereas macromolecules removal takes place via a rapid lymphatic drainage. Intra-
articular half-live of injected drugs alter between minutes and many hours, eg. 
soluble steroids half-time is between 1-4 hours and HA 12-24 h (Evans et al., 2014).  
 
A newer developed treatment against osteoarthritis is an autologous 
conditioned serum (ACS), which is injected into the joint after having been processed 
(Alvarez-Camino, Vazquez-Delgado, & Gay-Escoda, 2013; Baltzer M.D., Moser 
M.D., Jansen M.D., & Krauspe M.D., 2009; Wehling et al., 2007). ACS is an 
endogenous cell-free product and hence provides a patient with lower risk of side 
effects, like allergy, in comparison to reaction against other exogenous substances 
used in treatment. A standardized processing of ACS includes the collection of 50 ml 
Blood from a patient using special syringes containing about 200 chromium sulfate-
treated glass beads with a diameter of 2,5mm and a surface area of 21 mm2 
(Orthogen, Düsseldorf, Germany). These beads increase the nonpyrogenic surface 
area and induce a production of Interleukin-1-receptorantagonists (IL-1Ra), other 
cytokines and growth factors (Wehling et al., 2007). After having collected blood, 
samples are incubated at +37°C, centrifuged to separate the serum and then filled 
into 6-8 portions each containing 2ml (Baltzer M.D. et al., 2009). Samples are 
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afterwards frozen at -20°C and tested for HIV, Hepatitis B, and Hepatitis C (Baltzer 
M.D. et al., 2009). In a number of individually set sessions ACS is injected intra-
articularly.  
In comparison to PRP, ACS is a cell-free product without additives (Wehling et 
al., 2007). There are a number of possibilities to process PRP (Anitua, Sanchez, 
Orive, & Andia, 2007; Kon et al., 2010; Patel, Dhillon, Aggarwal, Marwaha, & Jain, 
2013), hence the outcome of randomized control trials (RCT) evaluating for PRP’s 
efficacy is inconsistent (Ayhan, Kesmezacar, & Akgun, 2014), unlike for ACS with its 
standardized processing (Wehling P., 2016). Another mentionable advantage over 
PRP is that to generate ACS a single blood drawing is enough, since it is possible to 
store and freeze ACS. To generate PRP a blood withdrawal before each injection is 
necessary (Wehling P., 2016).  
 
1.4 Genetic polymorphisms and its interaction with pain 
A single-nucleotide polymorphism is a variant of a single nucleotide within the 
genome at a specific position with a considerate existence for each variant in the 
population (>1%) (http://www.nature.com/scitable/definition/single-nucleotide-
polymorphism-snp-295).  
In many chronic pain disorders SNPs are known to play a vital role in 
expression and variation within an illness. SNPs occur when a single nucleotide –
adenine (A), thymine (T), cytosine (C), guanine (G) or uracil (U) in RNA- within the 
genome differs to the paired chromosome or members of the same species. They 
are associated with the expression of many diseases, however most of the time an 
interaction of many SNPs causes the manifestation of a disease. Very rarely, a single 
SNP is the sole cause for a disease, then called mendelian disease4. Density and 
variation of SNPs are affected by ethnicity and geography.  
SNPs can occur in any region of the genome, however the distribution is 
heterogeneous, they occur more often in non-coding regions than in coding-regions 
and intergenetic regions (Barreiro, Laval, Quach, Patin, & Quintana-Murci, 2008). 
The effect of a SNP depends on its location. SNPs within a coding region can lead to 
either synonymous change, meaning the sequence does not alter, or non-
                                                 
4 Mendelian Genetic Disorders Martin Alexander Kennedy, University of Otago, Christchurch, 
New Zealand 
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synonymous change -missense or nonsense SNP- meaning the amino acid 
sequence changes and the protein fold may vary. SNPs in non-coding regions can 
still have an effect upon genetic expression by influencing splicing, transcription 
factor binding to DNA or the stability of messenger RNA, more detail is given in 
chapter 6.1. 
As briefly mentioned above, SNPs can have a great effect upon the variation 
of an illness and upon the response of a drug. A special pain panel screens for 
carefully chosen genes and SNPs, which are known to play a role in key pathways of 
pain perception. With the help of this panel, results as mentioned below about COMT 
were collected. More detail will be given in Chapter 2.2 explaining the process of 
genome analysis.  
 
1.4.1 Genetic determinants of symptomatic OA pain  
A lack of correlation between radiographic evidence and pain rating is present 
in OA (Thakur et al., 2013). Lethbridge et al stated that out of a patient collective of 
675 Caucasians only 56% out of a subgroup with a Kellgren-Lawrence 3 were beset 
with joint pain (Lethbridge-Cejku et al., 1995).  
The search for genetic determinants in pain report of OA has obtained priority. 
Literature research has shown that certain genes have been identified to correlate 
with pain in clinically relevant OA: 
- SCN9A is a gene encoding for the alpha subunit of voltage gated sodium 
channel located on nociceptors and is known to be vital for pain-related 
signaling (https://ghr.nlm.nih.gov/gene/SCN9A). A gain of function of this gene 
was observed in fibromyalgia (Vargas-Alarcon et al., 2012), small fibre 
neuropathy (Faber et al., 2012) and primary erythromelalgia (Fischer et al., 
2009). Reimann et al showed that the SNP rs6746030 A/G (minor allele being 
A) leading to non-synonymous change Arg-1150-Trp, coding for arginine-to-
tryptophane substitution at codon position 1150 was implicated with an 
increased pain rating in OA, WOMAC being the assessment tool in a 
radiographic diagnosed OA cohort n=578 (Reimann et al., 2010). 
- TRPV1 is a gene encoding for a ligand-gated ion channel located central and 
peripheral eg on intra-articular nerve endings (Gavenis et al., 2009) and takes 
a central role in thermal and mechanical pain perception (Caterina, Rosen, 
Tominaga, Brake, & Julius, 1999; Christoph et al., 2007). Augmentation of 
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TRPV1-activity induced through proinflammatory factors was found to act as a 
central mediator for pain in OA as well as in other chronic pain conditions such 
as migraine, bone cancer and irritable bowel syndrome (IBS) (Alawi & Keeble, 
2010; Szallasi & Blumberg, 1999). Through phosphorylation via PKA- PKC-
dependent pathways and dephosphorylation TRPV1 can be sensitized and 
desensitized peripherally respectively, leading to an altered pain threshold 
(Moriyama et al., 2005). Proinflammatory mediators such as Prostaglandine 
E2 (PGE2), Prostaglandine I1 (PGI1) and Bradykinin (BK) can trigger the 
phosphorylation of TRPV1 and causing an augmented pain perception by 
lowering the threshold (Moriyama et al., 2005). Not only a qualitative change 
in TRPV1, but also a quantitative change of peripherally expressed TRPV1 on 
nociceptors can lead to an amplified pain report. Multiple authors showed that 
NGF-induced TrkA activation resulted in an enhanced expression of TRPV1 
(Fernihough, Gentry, Bevan, & Winter, 2005; Ji, Samad, Jin, Schmoll, & 
Woolf, 2002; Zhang, Huang, & McNaughton, 2005). 
An association between a bundle of SNPs in the TRPV1 gene and pain 
perception has been found (O'Neill et al., 2012). SNP rs8065080 C/T 
,Ile585Val allele, correlates with a reduced sensitivity to cold pain (Lotsch, 
Fluhr, Neddermayer, Doehring, & Geisslinger, 2009). The homozygote 
genotype Ile-Ile was found to implicate in a 25% lower risk for symptomatic, 
painful KOA (O'Neill et al., 2012; Valdes et al., 2011).   
- PCSK6 encodes for a paired amino acid converting enzyme 4 (PACE4), which 
belongs to the group of proprotein convertases. By activating cartilage-
degrading enzymes, ADAMTS-4 and ADAMTS-5 (short for a disintegrin and 
metalloproteinase with thrombospondin motifs), it plays a role in underlying 
pathomechanisms for developing OA (C. B. Little & Fosang, 2010; Seidah et 
al., 2008). 
Malfait et al discovered that in a cohort of total n=756 the minor allele G of 
rs900414 A/G was present with a much greater frequency in the asymptomatic 
KOA subgroup n= 156 in comparison to the symptomatic KOA subgroup 
n=600 (Malfait et al., 2012). This indicates that the presence of minor allele 
variant shields against pain in KOA.  
Miller et al showed that PCSK6 knock out mice did not develop pain-
associated movement limitations, as a sign for chronic pain, neither did they 
show central activation of microglia, in comparison to Wildtype mice after 16-
week period post destabilization of their medial meniscus (R.E. Miller, April 
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2014). Both indicate that diminished expression of PACE4 is a protection 
against painful OA. 
- Scientific literature proves that the SNP rs4680, aka Val108/158Met –
methionine substituting valine- found within the Catechol-O-Methyltransferase 
(COMT)5 gene leads to three different possible haplotypes, associated with 
different levels of pain sensitivity, low pain sensitivity, average and high pain 
sensitivity (Diatchenko et al., 2005). Patients who express the haplotype of 
high pain sensitivity show lower levels of COMT-activity by circa the factor of 
four (Lotta et al., 1995), leading to higher levels of catecholamine, like 
norepinephrine, epinephrine and dopamine. This polymorphism is associated 
with chronic pain conditions such as fibromyalgia (Gursoy et al., 2003) and 
temporo-mandibular joint disease (TMD) (Marbach & Levitt, 1976). Based on 
this, it has been found out that Propranolol, a nonselective β-blocker, can lead 
to a pain reduction in patients expressing the allele associated with lower 
levels of COMT expression (Tchivileva et al., 2010, p. 9). COMT was found to 
not only be involved in chronic pain diseases like fibromyalgia and TMD, but 
also to be related to OA-pain. Studies showed that the presence of the 158Met 
allele, resulting in a deduced activity of the enzyme, was linked with a 3-fold 
greater risk for hip pain in females (Tchivileva et al., 2010; van Meurs et al., 
2009). 
- Generally speaking, expression studies measuring genes functioning, found 
elevated expressions of proinflammatory factors such as Interleukin 1 and 
many other cytokines and proinflammatory factors (Thakur et al., 2013). For a 
detailed listing of genes and references view Thakur et al.  
 
1.5 Objective 
 The thesis is based upon a hypothesis-driven study looking at SNPs and 
genes that are known to be or have a strong likelihood to be involved in pain 
perception. The intent is to detect non-random associations between SNPs and pain 
rating and SNPs and treatment response in KOA patients.  
The first aim of this thesis was to evaluate SNPs involved in pain perception in 
order to gain greater insight in the underlying pathophysiology in symptomatic KOA. 
                                                 
5 COMT is a 271 amino acid large enzyme 
(https://www.ncbi.nlm.nih.gov/protein/CAG30308.1) degrading and inactivating 
catecholamines and other neuroactive substances by introducing a methyl group to the 
catechol structure. (https://www.ncbi.nlm.nih.gov/gene/1312; Tchivileva et al., 2010) 
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The further clinical use may be to act as a prediction on whether an individual patient 
diagnosis is associated with an increased or deduced pain report.   
 Secondly, the goal was to analyze for genetic polymorphisms correlating with 
the therapeutic response with ACS, HA and PL separately. This could act as the 
basis for a clinical application with a more patient-centered treatment and forecast. 
This study was the first report of genetic association in terms of treatment response 
to three different intra-articular modalities in symptomatic KOA patients. 
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2. Materials and Methods 
 
2.1 Description of the underlying clinical study 
The cohort we have used for our analysis has been collected for a study 
carried out in Germany by Baltzer et al. Their goal was to prove that treatment with 
autologous conditioned serum has a greater effect on pain reduction in comparison 
to HA and PL (Baltzer M.D. et al., 2009).  The study results were published in 
“Osteoarthritis and Cartilage” in 2009. The genetic analysis described here was 
carried out after the end of the treatments and was approved by the local Ethics 
committee Medical Faculty of Heinrich-Heine University Düsseldorf, which also 
approved the trial (study number 1988)6.  
 
In brief, the treatment study was carried as follows: it was a parallel-group 
design, randomized, 26-week prospective and double-blinded study –patients and 
observers were blinded, however doctors injecting not-. Beginning of 2003, Patients, 
diagnosed with primary knee OA, from five orthopedic centers7 have been recruited 
for the study. Volunteers were informed of procedures, risks and alternatives and had 
to give a written consent. Certain criteria of inclusion had to be fulfilled and are listed 
below: 
1. Patients had to be over the age of 30 years and of Caucasian race 
2. They had to be diagnosed with primary knee OA for at least three months 
before the study began 
3. Patients needed to be willing to pause pain medication and other NSAIDs for 
six months, in order to eliminate this as a possible confounder 
4. Their KOA had to be grade 2 or 3 on the Kellgren-Lawrence Scale, which 
classifies OA into 4 grades8.  
5. Their score on the visual analog scale (VAS) had to be above 50mm, on a 
scale of 0-100mm, to keep the Standard deviation low during analysis, 
consequently having a smaller dispersion of data. 
                                                 
6 see Annex V for the positive ethics votum  
7 involved orthopedic centers: Department of Orthopedics, Heinrich-Heine-University 
Hospital, Düsseldorf, Germany (recruiting institution); Centre for Molecular Orthopedics, 
Düsseldorf, Germany (recruiting institution and administration site of the study medication); 
Dr. Beckmann & Jansen Clinic, Mettmann, Germany (recruiting institution); Dr. E. Harnacke 
Clinic, Krefeld, Germany (recruiting institution) 
8See Annex I 
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6. Previous surgery was accepted, as long as it proceeded the time of first 
injection by at least three months 
Criteria of exclusion were as followed:  
1. Patients suffering from any systemic or inflammatory joint disease, suffering 
from crystalline or neuropathic arthropathy 
2. Patients suffering from bone cancer, metastasis or tumor-like lesions in 
immediate proximity to the treated joint 
3. Patients showing any hematologic or abnormal clinical values 
4. Pregnant or lactating women 
5. Patients abusing drugs 
6. Patients having had other intra-articular injections within the last six months 
before first injection 
7. Patients with known allergies against substances used in this trial, saline, HA, 
ACS 
8. Patients with a Kellgren-Lawrence scale grade 4 were not eligible  
Applying these inclusion and exclusion criteria 376 informed and volunteering 
patients initially took part in this study, underwent randomization and received in at 
least one knee one of the three treatment options –ACS, HA or saline as PL-. It was 
possible that one individual received treatment in both knees, however data only from 
the more severe knee and thus primary treated knee has been used for the study. 
The flowchart below shows each steps of screening and inclusion procedures, as 
well as detailed numbers of patients for each group at different times. Blood has 
been collected from patients of all three groups, however only blood samples from 
those patients within the ACS group underwent the processing of ACS as mentioned 
in the introductory part of this thesis. All patients had two appointments for three 
following weeks. Patients within ACS group received one 2ml injection of ACS per 
appointment, thus six injections in total. Patients within the Saline and HA groups 
received only one injection per week, a total of three injections, since the ethics 
committee did not allow a total of six injections of 1%-HA-solution and saline. Within 
the second appointment of each week within these two groups patients received a 
local/topical treatment with heparin cream.  
In the end, 345 patients completed the 26-week, prospective study.  
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Figure 1: This figure gives a brief overview on how data has been attained. Yellow boxes 
indicate recruitment of patients and their allocation to one of the treatment arms. For a more 
detailed description on how data has been collected and reasons for dropouts see review 
“autologous conditioned serum (ACS) is an effective treatment for knee osteoarthritis” 
((Baltzer M.D. et al., 2009). Algynomics and UNC prepared the genomic data set –here 
represented in green boxes- for statistical analysis, which was the focal point and 
assignment of this dissertation. The different tasks carried out within the framework of this 
thesis are listed in red boxes.  
 
Patients had to complete certain Questionnaires visual analog scale (VAS), 
Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Short-
Form 8 health-related quality of life survey (SF-8 HRQL) and the global patient 
assessment of treatment efficacy (GPA) throughout the trial at four different points in 
time, baseline-before the first injection-, 6 weeks, 3 months and 6 months after their 
last injection. In our analysis we have used data from VAS, a subjective statement 
464	pa ents	screened	
376	pa ents	randomized	
Tes ng	for	Inclusion	criteria	
134	ACS	treatment	 135	HA	treatment	 107	PL	treatment	
8	dropouts	 15	dropouts	 8	dropouts	
126 completed 26w 120	completed	26w	 99	completed	26w	
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about the current pain felt with a range from 0-100mm, and the WOMAC9, which is a 
disease-specified questionnaire, sub grouped into three categories, pain, physical 
function and stiffness, made up of 24 questions in total and a range from 0-240mm 
(Bellamy, Buchanan, Goldsmith, Campbell, & Stitt, 1988).  
 
 
Parameter 
 
Subgroups of therapeutic 
modalities 
 
   
ACS HA PL 
No. injected knees 
 
134 135 107 
Average age (y) 
 
53.8 ± 12.2 57.4 ± 12.0 60.3 ± 10.7 
Gender (f/m) 
 
65/69 74/61 68/39 
History previous knee 
surgergy (%) 
59.4 58.7 60.2 
WOMAC 
(0-10) 
Globalscore 
(mean) 
5.2 ± 2.3 5.2 ± 2.0 5.2 ± 2.1 
 
Pain (mean) 
 
5.2 ± 2.4 4.9 ± 2.1 4.9 ± 2.0  
Stifness (mean) 5.6 ± 2.8 6.0 ± 2.7 5.8 ± 2.8  
Function 
(mean) 
5.2 ± 2.4 5.2 ± 2.1 5.2 ± 2.2 
VAS (0-
100) 
  
69.6 ± 13.1 68.3 ± 12.8 66.3 ± 14.5 
 
Table 2: Display of baseline characteristics of patients -including average age, gender 
distribution, history of previous knee surgery- and the means with SD of baseline disease 
attributes of WOMAC and VAS. Clinical data collection and analysis was carried out by 
Baltzer et al (Baltzer M.D. et al., 2009) stating that statistically indistinguishable for all three 
subgroups. Analyzing for stratification and correlation between baseline demographics and 
treatment response showed no significant association (Baltzer M.D. et al., 2009). The table 
was adapted from Baltzer et al. To clearly state, this data has not been collected by me.  
  
                                                 
9 see Annex II 
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Time points for each  
subgroups Outcome scores    
    WOMAC   VAS 
   Global Pain Stiffness Function  
ACS 
(n=134) Baseline  
5.24 ± 
2.32 
5.18 ± 
2.39 
5.59 ± 
2.70 
5.21 ± 
2.41 69.6 ± 13.1 
 Week 7  
2.80 ± 
2.30  
2.71 ± 
2.37 
3.07 ± 
2.49 
2.80 ± 
2.34 33.8 ± 23.9 
 Week 13  
2.42 ± 
2.06 
2.33 ± 
2.14 
2.80 ± 
2.33 
2.40 ± 
2.08 29.6 ± 23.1 
 Week 26  
2.42 ± 
2.19 
2.42 ± 
2.25 
2.78 ± 
2.45  
2.37 ± 
2.21 29.5 ± 22.6 
        
HA (n=135) Baseline  
5.19 ± 
2.04 
4.89 ± 
2.12 
6.04 ± 
2.65 
5.17 ± 
2.11 68.6 ± 12.8  
 Week 7  
4.02 ± 
2.09 
3.63 ± 
2.09 
4.82 ± 
2.65 
4.04 ± 
2.14 52.6 ± 23.2 
 Week 13  
4.00 ± 
2.17 
3.73 ± 
2.22 
4.75 ± 
2.68 
4.00 ± 
2.19 52.1 ± 23.0 
 Week 26  
3.75 ± 
2.42 
3.59 ± 
2.47 
4.32 ± 
2.78 
3.74 ± 
2.44 49.3 ± 25.9 
        
PL (n=107) Baseline  
5.16 ± 
2.12 
4.86 ± 
2.01 
5.78 ± 
2.77 
5.18 ± 
2.24 
66.30 ± 
14.5 
 Week 7  
3.81 ± 
2.33 
3.49 ± 
2.23 
4.45 ± 
2.89 
3.83 ± 
2.42 
46.70 ± 
23.5 
 Week 13  
3.99 ± 
2.13 
3.61 ± 
2.11 
4.69 ± 
2.78 
4.01 ± 
2.20 
48.80 ± 
22.5 
 Week 26  
3.93 ± 
2.38 
3.68 ± 
2.24 
4.51 ± 
2.82 
3.94 ± 
2.48 
48.20 ± 
25.6 
 
Table 3: comparison of scores for WOMAC and its subgroups as well as for VAS for each 
treatment group at all four time points, showing dominance of ACS. (Baltzer M.D. et al., 
2009). Baltzer et al have carried out data collection and evaluation beforehand. To clearly 
state, this data has not been collected by me. 
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2.2 Technique of genome analysis  
Furthermore, DNA has been extracted from blood samples from the 345 
participants who completed the 26-week program. This DNA anonymized was 
transported to America and then underwent the Algynomics Pain Research Panel 
(http://www.algynomics.com/index.html), a panel designed by Alygnomics10 
screening for 3295 SNPs from 350 genes, which are known to be involved in pain 
report, hence it is a hypothesis-driven Panel in comparison to GWAS, genome wide 
association studies which are hypothesis free. Genes from the Algynomics Pain 
Panel were carefully chosen on their known involvement in nociceptive transmission, 
inflammation or psychological affects, such as mood (Smith et al., 2012). The Pain 
Research Panel allows researchers to carry out comprehensive analysis of genetic 
factors associated with clinical pain. It acts as the connecting key between genomic 
and phenotypic data and evaluates associations between these. This genetic raw 
data was the basis of this thesis. Specific and detailed genetic analysis in correlation 
to pain, function and treatment response were the focus of this work. 
 
2.3 Quality filtering 
The evaluated data set needed to undergo a filtering process, to raise its 
quality and reduce confounders as much as possible. The filtering can be divided into 
two groups. On the one hand there was filtering, looking at the samples itself. Any 
duplicates of samples as well as cases showing a genetic relationship between each 
other, non-Caucasians and mismatches in sex between phenotype and genotype 
were excluded. Samples undergo a detection filter with their values of probe 
intensity. Certain boundaries are set and if the SNPs value is outside these 
boundaries it is said to be a „No Call“. Hence, the call rate represents the SNPs 
detection. Samples and SNPs with a call rate below 0.95 were excluded.  
On the other hand, there is the filter looking at SNPs. Again duplicates, SNPs 
with a call rate below 0.95 were excluded. If the outcome of a set of data is 
repeatedly the same, it can be counted as valid and not false. SNPs with repeatability 
below 98% were excluded, to keep the validation as high as possible.  
Minor allele frequency (MAF) refers to the frequency of the less common allele of a 
sequence variation in a given population. It is used to distinguish between common 
                                                 
10 under the leadership of William Maixner, DDS, PhD, Luda Diatchenko, MD, PhD, Michael 
A. Hamilton, Roger B. Fillingim, PhD, Richard H. Gracely, PhD, Gary D. Slade, PhD, Jeffrey 
S. Mogil, PhD and Alex Sleptsov, PhD, MBA 
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and rare polymorphisms in a cohort 
(http://www.ncbi.nlm.nih.gov/projects/SNP/docs/rs_attributes.html). An allele is one of 
the possible forms a gene or a genetic locus can have caused by polymorphisms. 
SNPs with MAF below 1% are excluded because when one wants to make a 
meaningful statement about rare alleles, it requires a strong statistical power.  
Hardy-Weinberg-law states that allele or gene frequencies will stay constant 
from generation to generation: p2 + 2pq + q2 = 1. Samples and SNPs, which did not 
follow this equilibrium have been excluded from our set of data.  
 The process of quality filtering was carried out beforehand by Algynomics and 
by the University of North Carolina (UNC), as displayed in Figure 1.  
 
2.4 Regression model 
Regression tests are statistical models with the aim of detecting a non-random 
relationship between an outcome variable –dependent variable- and one or more 
independent variables. We have used regression analysis to identify certain SNPs 
with a strong predictive power for knee pain in KOA and for treatment response 
respectively. Statistical outline including chosen variables for our analysis and their 
general definition are delineated below (please see next page): 
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Dependent Variable  Question 1:  
level of pain (VAS or WOMAC) 
 
Question 2:  
treatment response calculated 
through difference between 
baseline pain rating and rating 
at week 26 
 
Therapeutic modalities:  
ACS -HA -PL 
 
The dependent variable  
changes in response to a 
deliberate change of the 
independent variable 
 
Independent variable  Question 1: presence of SNPs 
(recessive or dominant SNP)  
 
Question 2: presence of SNPs 
(recessive or dominant SNP)  
Change in the 
independent variable 
generates a change in 
dependent variable  
 
Covariates:  Question 1:  
BMI - age -history of previous 
surgery  
 
Question 2: baseline pain 
ratings as confounding 
covariate 
 
 
 
A covariate  may act as a  
predictive variable in an 
analysis, leading to an 
enhanced estimation of 
correlation between an 
independent and 
dependent variable. 
Possibilities are:  
- direct interest 
- confounding 
variable: the 
covariate 
associates with 
both dependent 
and independent 
variable, in a 
positive or inverse 
relation 
  28 
2.4.1 Idea behind choosing covariates 
We have carefully chosen three covariates to evaluate if these are possible 
factors influencing prediction of the outcome and pain report in KOA patients. The 
three covariates are age (WHO, 2013) (Hunter & Felson, 2006), history of previous 
surgery (WHO, 2013) and Body-Mass-Index (BMI)11 –weight(kg)/height(m)2-(Hunter 
& Felson, 2006) (Hunter, 2009) (Hochberg et al., 1995; WHO, 2013). Literature 
research validates that our covariates are known risk factors in OA.  
Higher levels of BMI are accompanied with a larger weight (kg) and may affect 
the pain report due to greater weight bearing onto the joints. Leptins effect may be 
the connecting factor between increased risk of OA and rising levels of BMI. Leptin, a 
18,64k Dalton protein produced by primarily adipocytes, as well as osteoblasts and 
chondrocytes may play a key role in KOA (Heidari, 2011). It is hypothesized that 
Leptin may not only have an influence on the hypothalamus regulating hunger but 
also on articular cartilage metabolism, activating pro-inflammatory pathways with the 
risk of a developing OA (Grazio & Balen, 2009; Sandell, 2009; Simopoulou et al., 
2007). Higher intra-articular levels of Leptin were observed in human OA (Dumond et 
al., 2003). Dumond et al provided “evidence that leptin plays a key role in the 
pathogenesis of OA via stimulation of the synthesis of growth factors and pro-
inflammatory mediators” (Dumond et al., 2003). 
In literature, an association between history of previous surgery –essentially 
arthroscopic procedures—and a strong neuropathic pain report, possibly caused 
through surgical manipulation rather than blunt trauma, was suggested (Valdes, 
Suokas, Doherty, Jenkins, & Doherty, 2014).  
Age may affect pain report in KOA patients. Many cross-sectional 
epidemiologic studies have shown that the prevalence of chronic pain increases with 
increasing age (Buskila, Abramov, Biton, & Neumann, 2000; Crook, Rideout, & 
Browne, 1984). It has to be kept in mind that bias for epidemiological studies on a 
complex topic like pain sensation exist. Depending on ethnic background, pain 
sensation may vary, hence results of this dissertation can only be applied to this one 
ethnicity.  
  
                                                 
11 BMI as a characteristics can not only function as a covariate but may also confound our 
results. Overweight may not only influence pain due to its mechanical force onto the joint, but 
also through chemical substances released by adipocytes which might modulate pain 
pathways and may falsify the outcome. 
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2.5 Software 
2.5.1 PLINK 
After the data underwent all quality filtering and has been cleaned, 272 
samples were left which were then ready to be analyzed using a special software, 
PLINK. PLINK, developed by Shaun Purcell, is a free-download toolset analyzing 
genome association of a dataset that is uploaded into the program. PLINK solely 
focuses on analysis of genotype and phenotype data and does not support any other 
steps prior to this, such as planning and the study design in general. PLINK is able to 
carry out a summary statistics for quality control, which gave proof that quality 
filtering as mentioned above was carried out in a correct manner. PLINKs quality 
control includes checking for missingness, sex checks and genotype frequencies 
amongst others (Chang et al., 2015). Furthermore, it is able to carry out basic 
association tests such as linear regression association studies, which has been 
mainly used in our analysis of finding SNPs associated with pain report and 
treatment response (Purcell et al., 2007). Regression tests are statistical models that 
try to associate an outcome variable with one or more independent variables. We 
have used this regression analysis to identify certain SNPs with a strong predictive 
power for knee pain, hence associate genotype with phenotype. 
 
2.5.2 Quantile-Quantile Plots 
Population stratification describes an event where allele frequencies differ in 
subgroups –case and control- within a population, misleading to a false association 
(Little J, 2009). It is a frequent cause for bias within genetic association studies. 
Baltzer et al. state in their paper that stratification analyses show no significance.  
Quantile-Quantile plots (Q/Q-plot) can be used to represent different statistical 
tests including a linear regression. The negative logarithm of a p-value is plotted in 
function of the negative logarithm of a p-value (p), divided by the number of SNPs (n) 
plus 1:  
-log (p/n+1) 
The x-axis plots the expected –log of p, the y-axis the observed –log of p and each 
dot on the graph represents one SNP. Derived from this, a Q/Q-plot shows whether 
the analyzed dataset underlies the Hardy-Weinberg-Equilibrium (HWE) (Little J, 
2009). When looking at the left bottom of the graph, SNPs should be in close 
adherence to the blue line „H0“ (expected in function of expected), which represents 
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the null hypothesis, then the likelihood of mistakes causing false results is lower and 
they are likely to follow HWE (Figure 2). Furthermore, SNPs with a very small p-value 
can be seen on the right top corner of the graph, since the negative logarithm is 
applied to emphasize a small p-value. The greater the deviation above the blue line, 
the greater the association between SNP and pain report.  
 A Q/Q-plot allows detection of “systematic bias due to deviation from HWE, 
population stratification, genotyping error” (J. Little et al., 2009) by interpreting the 
curve of the line (Pearson TA, Manolio TA 2008). 
 
Figure 2: -log Quantile-Quantile plot to illustrate regression test results. The blue line 
represents the null hypothesis: no association between any SNPs and pain report in KOA 
patients. Every red dot stands for a p-value for a SNP. Close adherence on the bottom 
corner tells us there is little false association or systematic bias. One SNP, top right corner 
above the blue line, shows strong association, since it does not adhere to the blue line. 
However, it does not show a significant one, since it does not pass the Bonferroni value, 
which would be at 4,5 of the negative logarithm. 
  
2.5.3 Lambda  
When carrying out association analyses, it is critical to test our statistics 
distribution in comparison with the expected null distribution. This can be done by 
designing Q/Q-plots (as it has been done above) and by calculating the genomic 
inflation factor. This factor, lambda (λ), is used to quantify the extent of inflation and 
false positive rate within a regression analysis. It describes the correlation between 
an independent and a dependent value. Goal is to achieve a value of λ=1. Values 
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deviating strongly from 1 may point out undetected confounders such as racial 
background, unknown familial relationships within our cohort, systemic technical bias 
or badly calibrated statistics. 
 
2.5.4 Manhattan Plots 
Manhattan plots, which can be designed using a program called HaploView, 
are another possibility to visualize associated SNPs to pain report and where they 
are located within the genome. The name „Manhattan“ plot is due to its similarity with 
the Manhattan skyline. It shows genomic coordinates on the x-axis, 23 chromosomes 
and the negative logarithm of associated p-value of SNPs on the y-axis (Figure 3). 
The greater the association, the smaller the p-value, hence the larger its negative 
logarithm. 
Each dot represents a SNPs p-value. Using a Manhattan plot it can be outlined which 
SNP has a strong association and on which chromosome it is located at
 
Figure 3: A colour-coordinated x-axis represents haplotypes or SNPs of each region on the 
genome that were tested, organized chromosome (each dot being one haplotype). The 
negative logarithm of p-value is displayed on the y-axis, representing the strength of 
association between the haplotype and the phenotype being measured. The greater an 
association, the smaller the p-value, hence when taking its negative logarithm, it will be 
larger and easier to illustrate visually. Each dot illustrates a SNP´s p-value in a regression 
model. The blue line indicates the gemone-wide significance niveau before the Bonferroni 
correction, which is explained further on in Chapter 3.1.  
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2.5.5 Linkage Disequilibrium diagrams 
Linkage disequilibrium (LD) describes a non-random relationship of genetic 
alleles and SNPs within a given population. In statistical analysis LD describes the 
spurious association between a SNP and a genetic expression. This SNP however 
only seems to be in a significant association with genetic expression – in our project 
pain report-, only because it is in strong LD with a SNP that has the actual impact on 
genetic regulation.   
Linkage disequilibrium can be caused due to limited recombination during 
meiosis within a chromosome; the consequence is that certain SNPs are to be 
inherited together above average. Certain hotspots of recombination exist and can be 
diagrammed via LocusZoom, a program, which will be explained in more detail 
further on in this thesis. Along to this, LD can be caused by mutation or genetic drift- 
the change in frequency of genetic variations-.  
The LD-coefficient r2 represents the correlation squared between two defined 
SNPs. It is outlined in a LD-box for two SNPs and can obtain values between r2=0, 
meaning the two SNPs are not inherited together, and r2=100, implying a complete 
inheritance of the two SNPs (Figure 4). LD measures the degree to which alleles at 
two different loci are non-randomly associated 
(https://www.ndsu.edu/pubweb/~mcclean/plsc731/Linkage%20Disequilibrium%20-
%20Association%20Mapping%20in%20Plants-lecture-overheads.pdf). 
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Figure 4: Figure 4 shows a LD-plot with r2, the LD-coefficients, for pairwise SNPs. Each 
square with its r2 represents the strength of a non-random relation between two SNPs. 
Location of the SNPs within the gene can be obtained on the white bar at the top.  
 
2.5.6 LocusZoom 
LocusZoom is a web-based tool developed by Prium et al. with the intention of 
visualizing GWAS12 results in an easy and publishable manner. The programs‘ 
functions are briefly listed below:  
• Visual display of regional information of a SNP in relation to genomic positions 
and other SNPs 
• Linkage disequilibrium and its magnitude to other SNPs → colour-coded 
points explained in legend in top right corner r2 
• Recombination patterns with hotspots → blue line on which spikes represent 
known recombination hotspots 
• Genes in close position to the region of interest → parallel to x-axis 
                                                 
12 Genome-wide association studies 
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This tool enables us to visualize more information of our index SNP as it will be 
shown along this dissertation. For further information and more detailed explanation 
see (Pruim et al., 2010).  
 
  
Figure 5: Model LocusZoom for the index SNP.  
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3. Results 
 
3.1 Question 1: evaluating SNPs associated with pain perception in KOA 
Due to the underpowered nature of our study -since there is a relative small 
sample size (n= 272)- the critical value of significance after the Bonferroni-correction 
was set to p < 1.892e-5. The Bonferroni-correction adjusts the significance threshold 
for the estimated effective number of independent SNPs, not the total number of 
SNPs in the Pain Panel due to false association via LD (Smith et al., 2012). Carrying 
out a linear regression analysis using PLINK four SNPs were found that have gotten 
close to our significance niveau.  
For our analysis we have used the phenotype of VAS and the pain category of 
the WOMAC at baseline. Hence, two sets of results were obtained for each linear 
regression test carried out. Results are shown below.  
 
Initial screening and data collection at baseline was carried out by Baltzer et 
al. Technical quality filtering of DNA was carried out in the US by University of North 
Carolina (UNC) and Algynomics. Tasks involved in this thesis were:  
- Generation of the study design  
- Data organization  
- Complex conduct of statistical analysis 
- Generating graphs and figures  
- Result interpretation and detailed discussion of results, downstream effect of 
SNPs and pathway analysis 
- Conclusion-drawing and clinical impact 
 
3.2 Linear regression analysis applying covariates 
As mentioned above, regression tests with covariates were also carried out. 
Our three covariates –age, history of previous surgery and BMI- were applied 
separately, as well as in combination of two or three covariates within a linear 
regression analysis.  
P-values tell us if an association between genotype/SNP and 
phenotype/altered pain perception exists. Beta reveals the actual effect of the SNP 
on altered pain report. If beta is a positive value, the SNP is associated with an 
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increment of pain report. Whereas a negative value of beta, indicates that the SNP is 
associated with a deduced pain report.  
Subchapters below show results for each covariate applied in linear regression 
analysis separately.  
 
3.2.1 Linear regression applying a combination of all three covariates 
 Primary analysis to have been carried out was a regression analysis where the 
three covariates are all taken into calculation.  
SNP Gene Chr p-value Beta 
WOMAC 
rs5224 BDKRB2 14 0.0002919 4.749 
rs7709656 GLRA1 5 0.0004998 4.728 
rs1236913 PTGS1 9 0.00105 6.472 
rs554576 CAT 11 0.001084 3.532 
VAS 
rs1888861 TrkA 1 0.0001526 -5.010 
rs548339 OPRM1 6 0.001716 3.879 
rs14138 PRKCE 2 0.001976 5.732 
 
Table 4: This table displays four most significant SNPs when WOMAC was applied and the 
three most significant SNPs under application of VAS including which gene they belong to 
and its molecular location (chromosome). rs5224 and rs7709656 come close to the 
significance threshold and set themselves apart from the following two SNPs with a much 
less significant p-value. Similar can be observed for rs1888861, delimiting itself with its p-
value from the following SNPs. Beta describes the direction and size of the effect on pain 
perception. Rs5224 and rs7709656 are associated with an increment in pain report in this 
dataset, whereas rs1888861 is associated with a decreased pain report.  
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6a. VAS 
 
6b. WOMAC 
Figure 6: the general shape of both Q/Q-plots (under application of VAS and WOMAC 
respectively) give reason to believe that systematic bias is absent in this regression analysis. 
Lambda 1.02. The marked dots represent the SNPs from Table 4 above, which show a non-
random association to altered pain report in participants of this study.  
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To estimate whether associations hold up without a particular covariate, 
regression analysis was carried out applying each covariate separately. If the 
association does not hold up, then the absent covariate could be counted as a 
confounder.  
 
3.2.2. Age as a covariate 
SNP Gene Chr p-value Beta 
WOMAC 
rs5224 BDKRB2 14 0.0002552 4.779 
rs7709656 GLRA1 5 0.0003759 4.799 
rs1236913 PTGS1 9 0.0009936 6.494 
rs554576 CAT 11 0.001156 3.505 
VAS 
rs1888861 TrkA 1 0.0001441 -5.042 
rs3758987 HTR3B 11 0.001354 4.497 
rs7825588 NRG1 8 0.00153 -0.254 
 
Table 5: Results for linear regression analysis when age is taken into account as a covariate 
are displayed in this table. Three SNPs in total were found with a stronger association, 
rs5224 and rs7709656 when WOMAC is used for the phenotypic data and one SNP, 
rs1888861, when VAS phenotype is used. The other listed SNPs have been added to the 
table to illustrate the deviation of rs5224, rs7709656 and rs1888861 from the rest.  
It can be observed that most significant SNPs for regression analysis when age is applied as 
a sole covariate do not differ from SNPs in analysis when three covariates are applied.  
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7a. VAS
 
7b. WOMAC 
Figure 7: a. Q/Q-plot applying VAS data with age as a covariate. The marked dot deviating 
from H0 represents the SNP rs1888861. By looking at the shape of the curve showing no 
general deviation from H0, systematic bias can be ruled out, Lambda 0.99. b. Graph 
represents data from table 5 using WOMAC data. The marked dots stand for the two most 
significant SNPs rs5224, rs7709656. Again, systematic bias can be excluded, Lambda 0.99.  
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The Quantile-Quantile-plots represent the relationship between the SNPs and 
their association to pain report in KOA. The Blue line illustrates the Null hypothesis: 
an association between SNPs and pain report in KOA patients does not exist. Dots 
deviated above the blue line represent our SNPs from table 5, which suggest a great 
association. Further, the data is not skewed and adheres to the blue line, indicating 
that association is true.  
 
3.2.3 History of previous surgery as a covariate 
SNP Gene Chr p-value  Beta 
WOMAC 
rs5224 BDKRB2 14 0.0001876 4.885 
rs7709656 GLRA1 5 0.0006763 4.613 
rs554576 CAT 11 0.001152 3.512 
rs10137185 ESR2 14 0.001323 -5.958 
VAS 
rs1888861 TrkA 1 0.0001264 -5.089 
rs548339 OPRM1 6 0.001656 3.330 
rs3780446 GABBR2 9 0.002499 -4.246 
 
Table 6: Results for linear regression analysis when history of previous surgery is taken into 
account as a covariate are displayed in this table. rs5224, when WOMAC is used for the 
phenotypic data, and rs1888861, when VAS phenotype is applied, showed a strong 
correlation p > 0.0002 to altered pain perception. Association between Rs7709656 and 
enhanced pain perception is present; the correlation is not as strong as in analysis with all 
three covariates. In comparison to analysis under application of all three covariates, SNPs 
with the greatest significance niveau overlap, indicating that history of previous surgery as a 
covariate does not confound the analysis. 
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8a. VAS 
 
8b. WOMAC 
Figure 8: a. and b. show Q/Q-plots applying VAS data and WOMAC data respectively with 
previous history of surgery as a covariate. The marked dots deviating from H0 represent the 
SNPs rs1888861 and rs5224 with the strongest association (p = 0.0001264 and p = 
0.0001876 respectively). Systematic bias can be ruled out due to a Lambda of 0.99 and the 
close adherence to H0, except for mentioned SNPs.  
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3.2.4 Body-Mass-Index (BMI) as a covariate 
SNP Gene Chr p-value Beta 
WOMAC 
rs5224 BDKRB2 14 0.0001194 4.999 
rs7709656 GLRA1 5 0.0004584 4.751 
rs1236913 PTGS1 9 0.001379 6.335 
rs554576 CAT 11 0.001548 3.431 
VAS 
rs3780446 GABBR2 9 0.001653 -4.457 
rs3758987 HTR3B 11 0.00175 4.445 
rs1888861 TrkA 1 0.09447 -5.231 
 
Table 7: Results for linear regression analysis when BMI is taken into account as a covariate 
are displayed in this table. Two SNPs in total were found with a stronger association, rs5224 
and rs7709656 when WOMAC is used for phenotypic data. Table displays furthermore the 
most significant SNP rs3780446 when VAS phenotype is used, however with a low level of p-
value. For comparison rs1888861 is listed. Both SNP are well below the significance 
threshold of p < 1.892e-5. 
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9a. VAS 
9b. WOMAC 
Figure 9: a. VAS. Using phenotypic VAS data, no SNP appear to pass or come close to the 
significance threshold of p < 1,892e-05. b. Using WOMAC phenotypic data, SNP rs5224 and 
rs7709656 are graphed above H0, coming close to the significance threshold. Lambda 1.01 
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3.3 Linear regression test without application of covariates 
After having found SNPs associated with alteration in pain report upon 
applying covariates, we looked at the results form regression analysis applying no 
covariates.  
SNP Gene Chr p-value Beta 
WOMAC 
rs5224 BDKRB2 14 0.0001269 4.968 
rs7709656 GLRA1 5 0.0004655 4.736 
rs1236913 PTGS1 9 0.001353 6.335 
rs554576 CAT 14 0.001459 3.442 
VAS 
rs1888861 TrkA 1 0.0000986 -5.206 
rs3758987 HTR3B 11 0.001723 4.444 
rs3780446 GABBR2 9 0.001758 -4.420 
 
Table 8: Table displays results of SNPs of the linear regression analysis when no covariates 
are applied. Again, the known SNPs rs5224, rs7709656 and rs1888861 correlate with a 
differed pain perception in regression analysis without applying covariates. Rs1888861 
comes very close to the significance niveau when no covariates are applied (p = 9.86e-05). 
Similar to above-listed regression studies under application of covariates, p-values of the 
three SNPs strongly deviate from p-values of the other SNPs tested.  
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10a. VAS 
10b. WOMAC 
Figure 10: Similar traits to the other regression analyses can be observed in graphed Q/Q-
plots applying no covariates. Rs1888861 as well as rs5224 and rs7709656 for VAS and 
WOMAC phenotype, respectively, noticeably deviate from H0, indicating an association 
between these SNPs and alteration in pain report.  
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Figure 11: Another possibility to visualize our index SNPs is through a Manhattan plot. SNPs 
and its belonging genes are marked on both plots for VAS and WOMAC, representing data 
from table 8.  On the top Manhattan plot it can be seen that rs1888861, TrkA located on 
chromosome 1 is segregated through its large –log of p; whereas when applying WOMAC 
data it can be seen that rs5224, BDKRB2 located on chromosome 14 and rs7709656, 
GLRA1 on chromosome 5 are secluded from others implicating possible clinical relevance.  
 
Analysis showed that rs5224 BDKRB2 and rs7709656 GLRA1 appear to be 
the top SNPs for all regression studies (under application of the phenotypic WOMAC 
data) with all three covariates applied, age alone, BMI alone and previous history 
alone. It can be concluded that our covariates do not confound the results when 
applied in combination or as a sole covariate. Presence of the minor allele of these 
two SNPs is continuously associated with an amplified pain perception in participants 
of the study.  
Further, regression tests showed that rs1888861 TrkA was constantly the SNP 
with the strongest association in altered pain report when using VAS as phenotypic 
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data. This can be said for all regression analyses, except for the analysis with BMI as 
a sole covariate, here rs1888861 was not associated with differed pain report. The 
minor allele of Rs1888861 TrkA appears to be associated with a diminished pain 
report. 
See table 9 below for visual depiction of collected information about SNPs.    
 
3.4 SNPs & Proteins 
SNP Gene Chr Location 
on Chr 
(bp) 
Protein Ligand Effect 
on pain 
report 
(beta) 
rs1888861 TrkA 1 155064585 Tropomyosin 
receptor 
kinase A 
neurotrophin, 
nerve growth 
factor (NGF) 
 
 
rs5224 BDKRB2 14 95777210 Bradykinin 
receptor B2 
Bradykinin, 
Kallidin 
 
 
rs7709656 GLRA1 5 151270918 glycin 
receptor 
alpha 1 
Glycin, β-
alanine, 
Taurine 
 
 
rs3780446 GABBR2 9 100111383 GABA 
receptor B2 
γ-
aminobyturic-
acid (GABA) 
 
 
 
Table 9: Four SNPs with its genes and proteins they encode for are shown in this table. 
Genes coding for proteins involved in receptor activity, its ligands are also illustrated. The 
fifth column represents the relationship between the SNP and its effect on the self-reported 
pain perception, either is the SNP associated with a reduction –rs1888861 TrkA- or an 
increase –rs5224 BDKRB2 and rs7709656 GLRA1- in pain report.  
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3.5 Replication of data 
Replication of our results using a different cohort was however not possible for 
each specific SNPs. Haploview enabled us to display which SNPs are in strong 
linkage disequilibrium –meaning the likelihood of being inherited together is high- 
with our reference SNPs, Figure 12. Using these SNPs with a strong LD, replication 
nonetheless was still not possible. P-values for SNPs in strong LD did not appear to 
be significant in the second cohort. To double check, we have marked SNPs, which 
were close to a significance level in the second cohort and looked at the strength of 
LD between those and our SNPs. This still did not achieve any possible results for 
replication.  
12a.        12b.  
12c.     12d.  
Figure 12: a. LD-plot for rs188861 in TRKA. b. LD-plot for rs5224 in BDKRB2. c. LD-plot for 
rs3780446 in GABBR2. d. LD-plot for rs7709656 in GLRA1 
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3.6 Lambda 
 A sum-up of outcomes for Lambda is shown below in Table 10 indicating the 
absence of any systematic bias in our analyses. 
Covariates Lambda λ 
None 1.01 
Age  0.993146 
History of previous surgery (preop) 1.01583 
BMI 1.00975 
Age, Preop 1.01592 
Age, Preop, BMI 1.01535 
 
Table 10: Λ was calculated using PLINK. Results show that our genomic inflation factor for 
each regression test is very close to 1. This suggests, that there is sufficient power and only 
very little confounds in our statistic, replicating what has been already observed by a close 
adherence on the Q/Q-plots.  
 
3.7 Possible association between found SNPs and treatment response with 
ACS 
The subchapters above describe an association between pain report in KOA 
patients and four SNPs. Along to this analysis, the question came up if these SNPs 
associated with pain report can also be associated with treatment response with 
ACS. To enable a comparison a linear regression analysis for treatment response 
only including patients treated with ACS was carried out.  
SNP Gene Chr Location 
on Chr (bp) 
p-value 
(VAS) 
p-value 
(WOMAC) 
rs5224 BDKRB2 14 95777210 0.2731 0.3157 
rs3780446 GABBR2 9 100111383 0.5872 0.6422 
rs7709656 GLRA1 5 151270918 0.9744 0.6945 
rs1888861 TRKA 1 155064585 0.9439 0.9311 
 
Table 11: This table displays results from a linear regression analysis only for the four SNPs, 
which were most significant in regression analysis for pain report. Again, regression analysis 
has been carried out twice, using VAS and WOMAC data. The two columns on the right 
stand for the significance niveau.  
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 p-values of this analysis are far off being significant, hence there was no 
association in our regression analysis between the four mentioned SNPs and 
treatment response to ACS. Imminent of this, these SNPs cannot be used as 
predictive markers for treatment response in KOA.  
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4. Treatment response 
As mentioned at the start, it is hypothesized that certain SNPs exist that can 
be associated with a treatment response to ACS, HA and saline as placebo. In the 
first part of our analysis we have found out that SNPs, which are associated with pain 
reports do not correlate with treatment response to ACS (Table 11). This chapter of 
the thesis will lay its focus upon the evaluation of regression analyses and 
comparison of SNPs for treatment response to the three subjects ACS, HA and 
saline. Treatment response was calculated by the difference of baseline pain rating in 
relation to pain rating at week 26. It should be kept in mind that baseline pain rating 
could act as a possible confounding variable in this set of regression analyses. 
 
4.1 Treatment response to ACS 
 First, we carried out a regression analysis for treatment response with ACS. 
The results of the five most significant SNPs are displayed in table 12. Nor SNPs or 
genes overlap with relevant SNPs in pain report -from the first part of this 
dissertation-. 
Results for the five most significant SNPs of regression analysis using WOMAC and 
VAS data for treatment response to ACS. 
SNP Gene Chr p-value Beta 
WOMAC 
rs502434 GRIA3 23 7.55E-05 1.399 
rs3782025 HTR3B 11 0.0002558 -1.133 
rs1518111 IL10 1 0.001306 -1.26 
rs624945 STAU1 20 0.002322 1.595 
rs9610496 MAPK1 22 0.002519 -1.208 
VAS 
rs9288452 ERBB4 2 0.0007988 1.456 
rs2274976 MTHFR 1 0.0008833 3.881 
rs9610496 MAPK1 22 0.00178 -1.331 
rs529520 OPRD1 1 0.002007 -1.144 
rs2391333 EFNB2 13 0.002217 -1.13 
 
Table 12: SNPs in table above are sorted in descending order by p-value when adjusting for 
WOMAC. As it can be observed rs502434 located in GRIA3 –coding for glutamate ionotropic 
  52 
receptor AMPA type subunit 3- is very close to passing the Bonferroni correction, implying a 
possible influence in treatment response to ACS.  
 
  
13a. WOMAC
 
13b. VAS 
Figure 13: Q/Q-plot graphically displaying two SNPs above the Null-Hypothesis H0. H0 is 
being calculated through expected p-value in function of the expected p-value In the top right 
corner is rs502434.  
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Subsequently further regression tests were carried out to see whether SNPs 
from table 12 can also be associated with treatment response under HA and saline.  
Comparison of 5 most significant SNPs in treatment response under ACS with 
treatment response under HA and saline show no correlation as it is graphed in table 
13.  
SNP Gene Chr p-value for 
ACS 
p-value for 
HA 
p-value for 
Saline 
rs502434 GRIA3 23 7.55E-05 0.3005 0.7309 
rs3782025 HTR3B 11 0.0002558 0.4685 0.8893 
rs1518111 IL10 1 0.001306 0.5566 0.9923 
rs624945 STAU1 20 0.002322 0.8947 0.4397 
rs9610496 MAPK1 22 0.002519 0.8022 0.1359 
 
Table 13: SNPs arranged in descending order of p-values for treatment response under 
ACS. The five most significant SNPs found in treatment response under ACS show no 
association, which could be explained using the results of the regression analysis with 
treatment responses under HA or saline.   
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4.2 Treatment response to HA 
Results for the five most significant SNPs of regression analysis using 
WOMAC and VAS data for treatment response to HA 
SNP Gene Chr p-value Beta 
WOMAC 
rs17689135 VPS4B 18 0.0005152 -1.38 
rs10011589 GRIA2 4 0.0008672 1.255 
rs10517665 GRIA2 4 0.001005 1.388 
rs1549758 NOS3 7 0.001121 1.067 
rs806368 CNR1 6 0.00117 -1.337 
VAS 
rs6490121 rs6490121 12 0.000962 1.176 
rs9291300 rs9291300 4 0.001327 -1.578 
rs17058952 rs17058952 8 0.002796 -1.107 
rs2293054 rs2293054 12 0.0029 1.17 
rs3792208 rs3792208 4 0.003371 1.17 
 
Table 14: rs17689135 and rs10011589 for WOMAC and rs6490121 for VAS show a slight 
significance in treatment response with HA in KOA patients, acknowledging bias opinions on 
the effect of HA. Jevsevar et al have concluded, based on a broad literature research, that 
there is no clinically important difference of injectable HA over PL in KOA patients (Jevsevar, 
Donnelly, Brown, & Cummins, 2015).  
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14a. WOMAC 
 
14b. VAS 
Figure 14a, 14b: Illustrating WOMAC and VAS results from Table 14 on a Quantile-Quantile-
Plot gives graphical evidence of absence passing the significance threshold in treatment 
response under HA, since SNPs adhere close to H0.  
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4.3 Treatment response to PL 
Results for the five most significant SNPs of regression analysis using 
WOMAC and VAS data for treatment response to PL. 
SNP Gene Chr p-value Beta 
WOMAC 
rs6698337 INADL 1 0.0007347 1.274 
rs2241054 EGFR 7 0.001153 1.124 
rs5917471 CYBB 23 0.00203 1.303 
rs11543848 EGFR 7 0.002313 1.281 
rs2239448 MAOA 23 0.003196 -1.183 
VAS 
rs4869817 OPRM1 6 0.001161 1.355 
rs403636 SLC6A3 5 0.001203 1.951 
rs12936511 CRHR1 17 0.002472 -2.608 
rs3750717 CPN1 10 0.002582 -3.592 
rs3729910 MAPK1 22 0.002735 -2.902 
 
Table 15: An association with p = 0.00074 between rs6698337 and treatment response to PL 
was observed when WOMAC data was applied. No further SNPs were associated with 
treatment response under application of WOMAC data. 
Regression analysis showed that no SNPs caused a significant difference in clinical 
appearance under PL when VAS was applied. Strongest association between a SNP and 
treatment response to PL lay at a p = 0.001161 for rs4869817 of OPRM1, which is far off 
from our Bonferroni-corrected p value of p < 1.892e-5. 
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15a. WOMAC 
 
15b. VAS 
Figure 15: SNPs for treatment response under saline acting as our placebo do not pass the 
significance niveau for a clinical relevance. All SNPs are located very closely to H0, 
implicating no correlation between SNPs and PL treatment response. 
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4.4 Outline of main points  
Table 16, 17, 18 and 19 outline the main points found in our study regarding 
Hypothesis 1 and 2. For all regression tests carried out and mentioned in this thesis, 
distribution on Q/Q-plots and Lambda as a control for population stratification implied 
no systematic deviation.  
 
Association between SNPs and pain report  
 
Phenotype Data 
 
WOMAC  VAS 
 
SNP 
 
 
rs5224 
 
rs7709656 
 
rs1888861 
 
Gene 
 
 
BDKRB2 
 
GLRA1 
 
TRKA 
 
Chr 
 
 
14 
 
5 
 
1 
 
Loaction of Chr 
(bp) 
 
 
95777210 
 
 
151270918 
 
55064585 
 
Pain Panel SNP 
 
 
C/T 
 
A/G 
 
A/G 
 
Minor allele 
 
 
T 
 
A 
 
G 
 
MAF 
 
 
0.128 
 
0.173 
 
0.190 
 
p-value  
 
 
 
0.0001194 –
0.0002919 
 
0.0003759 – 
0.0006763 
 
0.0000986 – 
0.0001526 
 
Beta 
 
 
4.749 – 4.999 
 
4.613 – 4.799 
 
-5.010 – -5.206 
 
Effect on pain 
 
 
 
 
 
 
 
 
Table 16: Please see next page for description of table 16. 
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Table 16: Recap of association results for the top-ranked SNPs in pain report in 272 
midstage KOA patients. The significance threshold after a spectral decomposition analysis –
to find the effective number of independent SNPs- was set to p < 1.892e-5. The listed SNPs 
come close to the significance threshold, but do not pass it. Table 16 displays range of 
significance niveau p for regression analysis in absence as well as in presence of covariates; 
p values do not diverge strongly within these analyses. Minor alleles of rs5224 C>T -T being 
the minor allele- (p 0.00029) and rs7709656 A/G -A being the minor allele- (p 0.0005) are 
associated with an increased pain report in KOA, whereas minor alleles of rs1888861 A>G – 
minor allele being G- (p 0.00015) correlate with a lowered pain perception.  
Minor allele G of rs1888861 (p = 9.86e-05) nearly passes the significance threshold in a 
regression test without any covariates applied.  
The row with p-values shows the range of results for all five regression tests carried out -
applying all covariates, each covariate separately and no covariates applied-. 
MAF displays the frequency of presence of the minor allele of a SNP.  
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Association between SNPs and altered treatment response to ACS 
 
Phenotype 
Data 
 
WOMAC VAS 
 
SNP 
 
 
rs502434 
 
rs3782025 
 
rs9288452 
 
rs2274976 
 
Gene 
 
 
GRIA3 
 
HRT3B 
 
ERBB4 
 
MTHFR 
 
Chr 
 
 
23 
 
11 
 
2 
 
1 
 
Loaction of 
Chr (bp) 
 
 
122364958 
 
 
151270918 
 
212895796 
 
11773514 
 
Pain Panel 
SNP 
 
 
A/G 
 
C/T 
 
C/T 
 
C/T 
 
Minor allele 
 
 
A 
 
C 
 
T 
 
T 
 
MAF 
 
 
0.402 
 
0.465 
 
- 
 
0.062 
 
p-value  
 
 
7.55e-5 
 
0.0002558 
 
0.0007988 
 
0.0008833 
 
Beta 
 
 
1.40 
 
-1.13 
 
1.456 
 
3.881 
 
Effect on 
treatment 
response 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 17: Outline of results collected for Hypothesis 2 is displayed. Under application of 
WOMAC phenotypic data, the minor allele A of rs502434 (glutamate ionotropic receptor 
AMPA type subunit 3) –with a frequency of 0.402- strongly correlates with response to ACS 
treatment with a significance of p = 7.55e-5, nearly passing the Bonferroni threshold. Further, 
minor allele C of rs3782025T>C (5-HT receptor 3B) –with a frequency of 0.465-, is 
associated to treatment response with a significance niveau of p = 2.56e-4. When VAS 
phenotype was applied, two different SNPs, rs9288452 and rs2274976 with a MAF of 0.009 -
minor allele T- appeared to correlate with an altered treatment response to ACS.  
MAF for rs9288452 C>T could not be calculated. 
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Association between SNPs and altered treatment response to HA 
 
Phenotype 
 Data 
 
WOMAC VAS 
 
SNP 
 
 
rs17689135 
 
rs10011589 
 
rs6490121 
 
Gene 
 
 
VPS4B 
 
GRIA2 
 
NOS1 
 
Chr 
 
 
18 
 
4 
 
12 
 
Loaction of Chr 
(bp) 
 
 
59236106 
 
 
158377702 
 
116192578 
 
Pain Panel SNP 
 
 
G/T 
 
A/T 
 
 
A/G 
 
Minor allele 
 
 
T 
 
A 
 
G 
 
MAF 
 
 
0.239 
 
0.158 
 
0.358 
 
p-value  
 
 
0.0005152 
 
0.0008672 
 
0.000962 
 
Beta 
 
 
-1.38 
 
1.26 
 
1.18 
 
Effect on 
treatment 
response 
 
 
 
 
 
 
 
 
 
 
 
Table 18: Correlations between the presence of minor alleles of 3 SNPs and varied treatment 
response to HA were found. P-values do not reach significance level and are less significant 
than results for ACS treatment response. 
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Association between SNPs and altered treatment response to PL 
 
Phenotype 
 Data 
 
VAS 
 
SNP 
 
 
rs6698337 
 
Gene 
 
 
INADL 
 
Chr 
 
 
1 
 
Loaction of Chr (bp) 
 
 
62110395 
 
Pain Panel SNP 
 
 
A/G 
 
Minor allele 
 
 
A 
 
MAF 
 
 
0.456 
 
p-value  
 
 
0.0007347 
 
Beta 
 
 
1.27 
 
Effect on treatment response 
 
 
 
 
Table 19: Only on SNP was found when carrying out regression tests to evaluate correlations 
between SNPs and alteration in treatment response to saline (PL). when using VAS 
phenotypic data, the presence of the minor allele A rs6698337G>A INADL was associated 
with a better treatment response to PL.  
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5. Discussion  
  
This chapter will first outline an attempt at translating the statistical results into 
clinical relevance and application. Besides, the chapter will focus on possible 
consequences on molecular level and alteration within pathways caused by SNPs 
and will go into further detail on gene analysis. Furthermore, an initial attempt of 
genetic involvement in pain report is made.  
 
Interpretation of statistical results with regard to clinical relevance for Hypothesis 1 
Pain perception in KOA:  
- BMI, age and history of previous surgery in KOA patients cannot be used to 
better predict a patient’s pain perception in KOA 
- Presence of the minor allele T of rs5224 C>T BDKRB2 as well as the 
presence of minor allele A of rs7709656 G>A GLRA1 are risk factors for an 
increased pain perception in KOA  
- Presence of the minor allele G of rs1888861 A>G TrkA protects against pain 
in KOA  
 
Interpretation of statistical results with regard to clinical relevance for Hypothesis 2 
Treatment response to ACS: 
- Patients with a present minor allele A of rs502434 G>A GRIA3 show an 
enhanced treatment response under intra-articular injected ACS against KOA, 
whereas patients with the minor allele C of rs3782025 T>C HRT3B show a 
reduced effect of injected ACS against their KOA 
- Correlations between these SNPs and treatment response were strong 
(7.55e-05 < p > 2.56e-04), nearly passing significance threshold of p < 1.892e-5 
 
Treatment response to HA: 
- Patients with the minor allele A of rs17689135 G>T VPS4B show a reduced 
response to intra-articular injected HA, whereas patients with the minor allele 
A of rs10011589 T/A GRIA2 and minor allele G of rs6490121 A>G NOS1 had 
a better response to HA treatment 
- Kept in mind that results of the association studies for HA treatment response 
did not pass the significance niveau (0.0005 < p > 0.000962) and did not 
come as close as results for ACS treatment response did 
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Treatment response to PL:  
- The presence of the minor allele A of rs6698337 G>A INADL may be 
associated with an increased treatment response under saline.  
- Again, results did not pass the significance threshold (p = 0.0007) and did not 
come as close to the threshold as results for ACS did  
 
5.1 Possible consequences of a SNP 
A SNP can occur in three different types of location within gene loci. The following 
will describe the aftereffect a SNP´s positioning might have within certain loci: 
1. Promoter region: the promoter region is positioned upstream from a gene 
toward 5’ (Sharan, 2007). It regulates transcription rate by acting as a secure 
DNA binding site for the RNA polymerase. The promoter region can be sub 
grouped into a core promoter, a proximal and a distal promoter (Juven-
Gershon, Hsu, Theisen, & Kadonaga, 2008): The Core promoter is made up of 
binding sites for RNA polymerases I-III and transcription factor binding sites, 
such as TATA-boxes. The proximal and distal promoters bind specific 
transcription factors. Once RNA polymerase and other necessary factors bind 
the promoter, transcription is initiated (Smale & Kadonaga, 2003). Further, 
transcription factors can bind the promoter and can either function as 
activators or repressors of transcription (J. D. Watson, 2013). SNPs within this 
region can cause an augmented or reduced transcription rate for a protein, 
which would lead to a quantitative change of the encoded protein. 
2. Coding region: the coding region is made up of exons, which carry genetic 
information for the mature RNA product, and introns. Non-coding Introns will 
be excluded during RNA transcription. This process is called RNA splicing. 
Polymorphisms within the coding region can therefore either be located within 
an intron or an exon. SNPs within an exon can cause altered functioning of a 
protein in different ways. A non-synonymous change –meaning the triplet 
codes for a different amino acid- will generate a variation in protein structure; 
whereas a synonymous change –meaning the encoded amino acid does not 
vary- may also impact downstream. 64 codons exist (61 coding for an amino 
acid and 3 stop codons, terminating translation) and only 20 different amino 
acids exist. Codons can be grouped into major and minor codons depending 
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on the present tRNA abundance. Through codon usage13, synonymous 
variants may have an impact upon mRNA secondary structure, regulating 
gene expression, speed of translation and protein folding downstream 
(Cortazzo et al., 2002; Kimchi-Sarfaty et al., 2007; Novoa & Ribas de 
Pouplana, 2012; Spencer & Barral, 2012).  
Intronic as well as exonic variants may regulate a genes expression by 
alternative splicing. SNPs within splicing enhancer regions can down and up 
regulate certain splicing variations (Guo et al., 2014).  
3. 3’ UTR (three prime untranslated region): downstream of the gene lays the 
three-prime region which does not code for the mature RNA product, however 
still plays an important role in gene expression. Stabilization –for example via 
polyadenylation-, export and translation efficiency is regulated by this region, 
which can be influenced by SNPs.  
MREs represent microRNA response elements, to which posttranscriptional 
gene-regulatory miRNA can bind. Numerous mechanisms exist –including 
binding mRNA at MREs, destabilizing mRNA, inhibiting polyadenylation or 
acting as initiation blocks for ribosome assembly-, where miRNA play a key 
role leading to translational repression, meaning the observation of a greater 
decrement in protein product compared to the decrement of levels of mRNA 
(Baek et al., 2008; Gu & Kay, 2010).  
AU-rich elements in the 3’ UTR region display binding sites for proteins, which 
again can affect mRNA degradation and translation rate (Barrett, Fletcher, & 
Wilton, 2012).  
Further sequence involved in affecting mRNA’s stabilization, export and 
translational efficiency is the Poly(A)tail, to which gene-regulatory proteins can 
bind. Polyadenylation is associated with a translation-activating characteristic, 
whereas the absence is associated with a decay of mRNA (Wilusz, 
Wormington, & Peltz, 2001).  
 
 
                                                 
13 Codon usage describes the usage of synonymous codons at different frequencies within 
the genome varying from species to species (Plotkin & Kudla, 2011).  
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Figure 16: This illustration depictures possibilities of SNPs positioning with its result on 
transformation and protein structure as described above.  
MREs: microRNA response elements 
AREs: AU-rich elements 
TF: transcription factors 
miRNA: microRNA 
 
Overall, SNPs in all three regions of a locus can have a quantitative as well as 
a qualitative alteration of mRNA and downstream protein as a consequence. 
 
With the help of NCBI14, our SNPs could be associated to regions within their 
encoded gene. It is an initial attempt to seek an idea of how our SNPs cause a 
change in protein functioning and affect pain report in KOA.  
 
SNP Gene Position on 
Chr (bp) 
Region Consquence 
rs1888861 TrkA 155,064,585 coding region intron variant 
rs5224 BDKRB2 95,777,210 - synonymous 
codon 
(Thr264Thr) 
rs7709656 GLRA1 151,270,918 coding region intron variant 
rs3780446 GABBR2 100,111,383 coding region intron variant 
 
Table 20: SNPs within the three genes TrkA, GLRA1, GABBR2 lead to an intronic variant 
within the DNA sequence. Rs5224 prompts to a synonymous codon, meaning the amino acid 
sequence does not differ. Synonymous codon rs5224: ACG -> ACA both coding for 
threonine with a frequency of use of 6.11 and 15.1 in 1000bp (data from Codon Usage 
Database, which uses NCBI-GenBank) 
                                                 
14 National Center for Biotechnology Information 
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5.2 Analysis of SNPs estimated to be involved in treatment response under 
ACS 
 
Table 21: The presence of two of the index SNPs rs502434 and rs624945 are allied with an 
increment in treatment response to ACS, meaning a better score in WOMAC and a lower 
score VAS. Slade et al have shown that raised levels of IL 8 and other cytokines correlate 
with the sensitivity to pain in patients with TMD –temporomandibular disorder- (Slade et al., 
2011) implicating that pro-inflammatory substances have an impact upon chronic pain 
disorders.  
 
Using web based research via NCBI, pathwayLinker and results from the 
regression analysis via PLINK further information has been collected which is being 
displaying in Table 19. This information includes the protein the genes encode for, 
                                                 
15 Converting 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, which is a co-
substrate in the remethylation from homocysteine to methionine 
 
SNP 
 
Gene Protein Ligand/ 
Function 
of protein 
SNP‘s 
effect 
Effect on 
treatment 
response 
(beta) 
WOMAC 
rs502434 GRIA3 ionotropic glutamate 
receptor AMPA type 
subunit 3 
Glutamate synonymous 
codon 
 
 
rs3782025 HTR3B 5-hydroxytryptamine 
receptor type B 
Serotonin intron 
variant 
 
 
VAS 
rs9288452 ERBB4 Erb-b2 receptor tyrosine 
kinase 4 
Epidermal 
growth 
factors 
(EGF) 
Intron 
variant  
 
 
Rs2274976 MTHFR methylenetetrahydrofolate 
reductase 
Enzyme15 Intron 
variant 
(missense) 
 
 
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their ligands or functions of the protein, the SNPs effect within the genome and its 
effect on treatment response to ACS.  
 
rs502434 is located on the X-chromosome within GRIA3, encoding for the 
subunit 3 of the ionotropic glutamate receptor of AMPA type. AMPA acts as an 
excitatory receptor in neurophysiological pathways in the mammalian brain. 
Literature suggests that SNPs within GRIA1 and GRIA3 play a critical role in cortical 
depression and migraine with and without aura.  (Formicola et al., 2010). Further 
literature check on GRIA gave insight on a novel idea implicating AMPA receptors as 
possible targets in therapy for pain-induced depression. Goffer et al suggest that 
enhancement of AMPA in the nucleus accumbens can reduce depression-like 
behavior in chronic pain conditions. (Goffer et al., 2013). Approaching with the idea of 
a multifactorial origin of pain including a psychological component, it should be kept 
in mind that depression-like behavior can enhance the sensation of pain and hence 
the subjective sensation of response to a certain treatment. Results in our study have 
shown that the presence of the minor allele of SNP rs502434 correlates with a better 
response to ACS.  
 
5.3 SNP effects on gene expression  
 The web based tool GTex enabled us to i) look up if a SNP has an effect on 
gene expression and ii) in what tissue the association was found in, described as 
expression quantitative trait locus (eQTL). Sadly, we only found data about gene 
expression in interesting tissues for two of our SNPs, rs1888861 and rs5224. GTex 
did not include data for other SNPs involved in alteration of pain perception and 
treatment response. 
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17a.  
 
 
17b.  
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17c.  
Figure 17: Gene expression levels by genotype. Box plots designed by GTex with a sample 
size with genotyping n=7333 of a donor set n=449 (Consortium, 2013; 
http://www.gtexportal.org/home/).  
 
a) Rs1888861: Selected tissue tibial nerve. In presence of a homozygous genotype of 
the minor allele G/G n=12 an enhanced gene expression is measured. The 
heterozygous genotype only results in a slight increase in TrkA expression. 
Rs1888861 appears to follow a recessive genetic trait, because only the presence of 
both minor alleles causes an augmentation in gene expression.  
b) Rs5224: selected tissue cerebellum. The homozygous genotype of the minor allele 
T/T n=4, as well as the heterozygous genotype n=23, leads to a nearly equally great 
increment in BDKRB2 expression, indicating a dominant genetic trait, since the 
occurrence of one minor allele already has an impact upon gene expression, when 
cerebellar tissue is analyzed. 
c) Rs5224: selected tissue cerebellar hemisphere. The Homozygous genotype of the 
minor allele T/T n=4 generates a greater augmentation of gene expression than the 
heterozygous genotype n=25. The homozygous genotype of the major allele C/C 
n=74 is associated with a decrement in gene expression of BDKRB2.  
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SNP homozygote 
genotype 
minor allele 
minor allele 
homozygote 
genotype  
frequency 
heterozygote 
genotype 
frequency  
alternative 
allele 
homozygote 
genotype 
frequency 
rs5224 (C/T) T/T 0.018 0.221 0.761 
rs7709656 (A/G) A/A 0.035 0.274 0.690 
rs1888861 (A/G) G/G 0.053 0.274 0.673 
 
Table 22: Data taken from the international HapMap Project of 90 DNA samples from a Utah 
US population with Northern and Western European ancestry (CEU) (International HapMap, 
2003) functioning as a representation for genotype frequencies in our Caucasian cohort. In 
table 22 the 3 possible genotype frequencies for an allele of the genes found to be involved 
in pain perception in KOA are displayed.  
 
5.4 Pathway analysis for genes found to be involved in pain report 
 
Accompanying the search of the altered protein structure, a pathway analysis 
may give a greater insight on how genes, on which the four SNPs are located, 
interact and in which signaling pathways they are known to be involved in. A Pathway 
Software, PathwayLinker, enabled us to carry out separate searches for each of our 
four genes, GABBR2, TRKA, BDKRB2, as well as displaying certain interactions in 
different pathways.   
 
5.4.1 Pathway analysis for TrkA 
 Tropomyosin receptor kinase A was found to be involved in a handful of 
pathways, including pathways in -cancer thyroid cancer (Frattini et al., 2004)-, 
apoptosis as well as MAPK signaling pathway (Figure 18), neurotrophin signaling 
pathway (Figure 19) and inflammatory mediator regulation of TRP channels, which 
will be explained in more detail further along this dissertation.  
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 Figure 1816: RTK stands for receptor tyrosine kinase, GF for Growth factors, to whom NGF, 
BNDF and NT3, 4 (being subgroups of NGF) belong. TrkA (displayed as RTK) is activated 
when NGF (nerve growth factor) (displayed as GF), BDNF (brain-derived neurotrophic factor) 
and NT3, 4 (Neurotrophin 3, 4) bind the receptor, which all belong to the family of 
neurotrophins. A cascade of phosphorylation via Ras, Raf, MEKK and MEK leads to an 
                                                 
16 http://www.genome.jp/kegg-
bin/show_pathway?scale=0.67&query=&map=hsa04010&scale=0.82&auto_image=&show_d
escription=hide&multi_query= 
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activation of ERK (Extracellular signal-regulated kinase). cPLA2 (cytosolic phospholipase A2) 
furthermore participates in TRP channel activation, which was found out to be another 
intersection of our most significant genes (Vriens et al., 2004).  
 
 
Figure 1917: Neurotrophin-mediated dimerization and phosphorylation of a certain loop of the 
Trk receptors activate these receptors (Huang & Reichardt, 2003). TrkA has been found to 
be involved in the neurotrophin signaling pathway, via the MAPK pathway it results in a 
regulation of neurite cellular differentiation, functioning and outgrowth (Reichardt, 2006).  
                                                 
17 http://www.genome.jp/kegg-bin/show_pathway?hsa04722 
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5.4.2 Pathway analysis for BDKRB2 
 BDKRB2 is located on the long arm of chromosome 14 –exact location is 
14q32.1-32.2- and encodes a receptor for Bradykinin, a 9aa long peptide. Bradykinin 
evokes responses including vasodilatation, edema, smooth muscle spasm and pain 
fibre stimulation (http://www.ncbi.nlm.nih.gov/gene/624). Presence of the Minor allele 
of rs5224 C/T -T being the minor allele- has been associated with a greater pain 
report in patients with KOA in this analysis.  
 BDKRB2 plays a role in the activation of the cGMP-PKG signaling pathway. 
This pathway is also connected to the MAPK signaling pathway (Figure 20) as well 
as the phosphatidylinositol signaling system, which is involved in membrane 
trafficking, hence it can have an influence upon levels within the cell, the release of 
proteins and internalization from extracellular.   
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Figure 2018: After binding the vasoactive peptide, Bradykinin, downstream sGC (soluble 
guanylyl cyclase) is activated which raises the level of cGMP within a cell. Higher levels of 
cGMP lead to an activation of PKG (protein kinase G), which then again activates the MAPK 
signaling pathway by phosphorylating Raf-1(see image).  
 
5.4.3 Analysis for GABBR2 and GLRA1 
 GABA and glycine are the main inhibitory neurotransmitters in the dorsal horn 
(Lamina I and II are GABA dominated, whereas Lamina III and deeper are controlled 
by GABA and glycine)(Todd & Spike, 1993). The so called gate control theory 
                                                 
18 http://www.genome.jp/kegg-bin/show_pathway?hsa04022+624 
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suggests that inhibitory GABAergic and glycinergic interneurons in the spinal cord 
control the delivery of pain signaling to higher brain areas (Zeilhofer, Wildner, & 
Yevenes, 2012). Widespread opinions exist that inhibitory neurons play a critical role 
in pain perception and that dysfunctions in these inhibitory glycenergic and 
GABAergic systems are pathological mechanisms in many pain conditions including 
neuropathic pain, allodynia and hyperalgesia (Hwang & Yaksh, 1997; Kuner, 2010; 
Sandkuhler, 2009; Zeilhofer et al., 2012). Suppressing GABA and glycine neurons 
led to an enhanced reaction to pain and by agonizing GABA in neuropathic 
conditions a reversing of hyperalgesia has been observed in many different rat and 
mice models respectively (Foster et al., 2015; Malan, Mata, & Porreca, 2002). Foster 
et al showed that through toxin-dependent ablation or silencing of glycine neurons a 
mechanical and thermal hyperalgesia and itch developed in mice models (Foster et 
al., 2015). 
Mechanisms that underlie the malfunctioning of the inhibitory system such as 
reduced concentration of GABA and glycine (Moore et al., 2002; Muller, Heinke, & 
Sandkuhler, 2003; Scholz et al., 2005), reduced responses of postsynaptic glycine 
receptors (Ahmadi, Lippross, Neuhuber, & Zeilhofer, 2002; Harvey et al., 2004) are 
present in chronic pain states.  
Interestingly the activation of inhibitory neurons can lead to an alleviation of 
neuropathic pain in certain situations. Peripheral nerve damage leads to higher 
BDNF concentrations via inflammatory processes, which then again leads to a 
downregulation of the potassium-chloride co –exporter KCC2 (Coull et al., 2003). The 
result is a membrane depolarization from -75mV (under non-inflammatory 
circumstances) to -50mV. The consequence of this pathomechanism is a switch from 
inhibitory functioning (via hyperpolarization) to an excitatory mechanism in pain 
processing (Coull et al., 2003).  
Consequently, the presence of the minor allele A rs7709656 GLRA1 (p 0.0005) -
which was found to be associated with an increased pain perception in midstage 
KOA- may possibly be due to a disinhibition in the glycenergic system.  
 
GABA-receptor B2 is a metabotropic channel, which is linked to a potassium channel 
via a G-protein GNB. Its activation through the endogenous inhibitory 
neurotransmitter GABA leads to a hyperpolarization, hence an inhibitory postsynaptic 
potential.  
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Figure 2119: GABA-receptor B is located pre- and postsynaptic. Presynaptic receptors 
functioning is a negative auto feedback, regulating its own release. Postsynaptic GABA B-
receptor subunit 2 heterodimer with GABBR1 (GABA B-receptor subunit 1). Only the 
                                                 
19 http://www.genome.jp/kegg-bin/show_pathway?hsa04727+2555 
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heterodimerization allows a functionally active GABA B-receptor, GABBR2 on its own cannot 
elicit a response downstream(Margeta-Mitrovic, Jan, & Jan, 2000; White JH, 1998). 
 
5.5 MAPK signaling pathway 
An observed interface for three genes –TrkA, GABBR2, BDKRB2- was found. 
Via PathwayLinker it has been observed that the three genes activated the MAPK 
signaling pathway amongst others.  
Mitogen-activated protein kinases (MAPKs) are important for intracellular signal 
transduction and play critical roles not only in cell differentiation, proliferation but also 
in regulating neural plasticity and inflammatory responses. (Ji, Gereau, Malcangio, & 
Strichartz, 2009, p. 1). MAPKs include three major representatives, each standing for 
its own signaling pathway:  
1. Extracellular signal-regulated kinases (ERK1, 2, 5) 
2. p38 (p38, p38, p38, p38) 
3. c-Jun N-terminal kinase (JNK1, JNK2, JNK3) 
Earlier studies have shown, that ERK activation is dependent on nociceptive activity. 
In normal conditions, ERK is activated by high-threshold mechanical stimulations, 
this however changes after injury -also in joints- (Ji et al., 2009, p. 4), as it happens in 
osteoarthritis, posttraumatic and during surgery. Hence, the threshold for pain is 
reduced. Different mediators, transmitters and pathways can activate ERK 
downstream in the dorsal horn neurons. The activated ERK leads to translational (via 
CREB gene expression of proinflammatory mediators and receptors such as and 
COX-2 and TrkB is upregulated) as well as post-translational changes (recruiting 
NMDAR, decreasing K+ currents via phosphorylation and hence increasing 
membrane excitability) both inducing or maintaining central sensitization(Latremoliere 
& Woolf, 2009). Further a persistent pain condition –with reference to a lowered pain 
threshold-, like knee osteoarthritis can cause a phosphorylation of MAPKs, thus 
activating its pathway. Downstream, the synthesis as well as a rapid release of 
proinflammatory and pronociceptive mediators such as COX2, IL-1 (Kumar et al. , 
2003) and TNF (Boyle et al., 2006) is stimulated. p38 was found to play a central 
role in inflammation (Boyle et al., 2006; Kumar, Boehm, & Lee, 2003). Ji also 
proposed and explained how MAPKs take up a crucial part in central sensitization of 
pain report (Ji et al., 2009). 
 To sum up, the interaction between our genes and MAPKs may act as an infant 
attempt to possibly explain how pain is being perceived differently in mid-stage KOA 
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depending on the presence or absence of certain SNPs, which are again linked with 
pathways involving MAPKs and possibly causing a sensitization of pain. 
Nonetheless, it is not seen as necessary to find a single cause to explain all SNPs 
correlation; a multifactorial origin on genetic level should stay in consideration.  
 
5.6 GPCR (G protein-coupled receptors) 
Our found genes encode receptors that all have one characteristic in common: 
they are G protein-coupled receptors, one of the largest receptor type families with 
over eight hundred receptors (http://www.ncbi.nlm.nih.gov/biosystems/1269544). 
After having received an external stimulus -GABA, Bradykinin, Glutamate or 
Neuropeptides- it comes to a conformational change. GTP replaces GDP and the  
subunit dissociates, leaving G complex. GPCRs are known to have the ability to 
modulate various pathways, including MAPK signaling (Figure 22) 
(http://www.ncbi.nlm.nih.gov/biosystems/1269574?Sel=geneid:624&report=Abstract#
show=proteins).  
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Figure 22: Please see next page for description of figure 22. 
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Figure 2220: GPCR superfamily includes a great variety of receptors. Via G subunit Ras is 
activated and leading to an activation of MAPK signaling pathway, which can as mentioned 
above influence pain perception by central sensitization on molecular levels and immediate 
release of pronociceptive mediators (Ji, Gereau, Malcangio, & Strichartz, 2009, p. 1).  
 
5.7 Link between TrkA, BDKRB2 and TRP-channels 
Nonselective Ca2+-permeable Transient receptor potential channels are built 
from six transmembrane regions (Huynh, Cohen, & Moiseenkova-Bell, 2014). Six 
subfamilies exist, including TRPA and TRPV (Bidaux et al., 2015).  
TRPA1 (ankyrin 1) receptors are associated with inflammation and nociception. Via 
PathwayLinker a relation between TrkA and TRP-channel signaling as well as 
between BDKRB2 and TRP-channel signaling was found (Figure 23).  
TRPV1 is well known as the Vanilloid-receptor, functioning as a nociceptor in free 
nerve endings and can be activated by capsaicin, piperin (pepper), high temperature 
(>43°C), endogenous cannabinoids, acidic environment (pH<5.2) and 
proinflammatory substances (Gavenis et al., 2009; Szallasi & Blumberg, 1999).  
NGF and BK -two mediators involved in underlying inflammatory 
pathomechanisms of OA- cause a sensitization and higher expression of TRPV1 in 
nociceptors via TrkA-dependent and BDKRB2-dependent-pathways –activating PKC 
downstream, which then phosphorylates TRPV1 at different receptor sites-, as it has 
been outlined in 1.4.1 (Zhang et al., 2005). This proves that a direct interaction 
between TrkA, BDKRB2 and TRPV1 exists, which has the potential of altering pain 
perception.  
 Shi et al. presented results, which showed that the pain threshold in patients 
with IBS (irritable bowel syndrome) can be regulated by TRPV1 inhibitors, resulting in 
a higher threshold (Shi et al., 2015, p. 4857). Derived from this, the idea that TRP 
channels can regulate pain thresholds generally in chronic pain conditions may also 
be applied and proven for knee osteoarthritis. As delineated in Chapter 1.4.1, many 
SNPs have already been associated with pain perception in OA (O'Neill et al., 2012).  
 To conclude TRPV1, TRPA1, TRPM8 play a role in inflammatory processes 
and pain mediation in chronic pain patients (Wang et al., 2015, p. 11) and it may be 
worth exploring more in the field of possible associations and interactions between 
TrkA, BDKRB2 and TRP-channels.  
 
                                                 
20 http://www.genome.jp/kegg-bin/show_pathway?hsa04014+10681 
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Figure 23: Please see next page for description of figure 23. 
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Figure 2321: Tissue injury and a variety of inflammatory mediators can bind TrkA (NGF) and 
Bradykinin can lead to the oligomerization of BDKRB1 and 2. This Figure visually illustrates 
the connection between TrkA and TRPV1/TRPA1 and the relation of BDKRB2 with 
TRPV1/TRPA1(Katanosaka et al., 2008).  
 
5.8 Future aspects 
  Many experts are of the opinion that with the momentary trend of 
increased aging and obesity in the industrialized world, sufficient management of OA 
becomes of great priority, with some of the goals being the delay of arthroplasty, 
decelerating the progress of degeneration or even reversing the degenerative 
process (Fibel, Hillstrom, & Halpern, 2015). Understanding the underlying 
pathophysiological mechanisms including pain perception in symptomatic KOA 
patients is crucial for improvement in disease-modifying treatment options. 
 In this thesis the goal of detecting SNPs non-randomly associated with 
pain report and treatment response has been fulfilled. In order to validate our 
observed data replication in an independent set of data should be realized. Another 
attempt to verify our results can also be achieved through a different study design 
based on a comparison of pain rating and treatment response between cohorts of 
patients that present the minor allele of a SNP and patients that present the major 
allele of that SNP; the independent variable being the allele of a SNP and the 
dependent measured variable the pain report through standardized questionnaires, 
WOMAC and VAS e.g.  
 Another attempt of finding a set of data that acts as a replication to our most 
significant SNPs or to SNPs which are in strong LD should be tried out, to strengthen 
the results described in this thesis.  
Further, these results give rise to questions such as how does a SNP have an 
effect upon the encoded protein and via which regulatory mechanisms may it cause a 
change in pain perception? Quantitative and qualitative measurements of modified 
proteins may give a greater insight on pathophysiology behind altered pain report.  
 After having analyzed possible pathways, which proteins and receptors are 
known to be involved in, the question comes up –with the knowledge that MAPKs 
activation plays a critical role in induction and maintenance of inflammatory as well 
as neuropathic pain- on how do modified receptors interact and influence MAPK 
signaling pathway in pain perception. 
                                                 
21 http://www.genome.jp/kegg-bin/show_pathway?hsa04750+624 
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5.9 Possible limitations of this study 
 A certain reference SNP can be in association to another SNP through linkage 
disequilibrium, meaning that the observed association between a SNP and a 
phenotype –altered pain report and altered treatment response in Hypothesis 1 and 
2, respectively- is not causal. The actual function of the reference SNP can be 
inferred based on its position in or near a gene, due to LD between SNPs. For 
example, a synonymous variants regulation on a genes expression can be explained 
through linkage disequilibrium. The synonymous variant may show a correlation with 
another SNP that determines the actual impact on the gene regulation. This non-
random association can be exposed using the software mentioned above. This 
counts as a possible limitation to this thesis.  
 Due to the population-specific analysis, Caucasians only, impact limitations 
may arise, and results may not be applicable for other ethnic groups.  
 The presence of LD between SNPs led to a critical significance niveau of p < 
1.892e-5, which is in combination with the underpowered study difficult to pass.  
 Another aspect is that a certain phenotype (altered pain report) can arise from 
different genotypes, having a complex trait.  
Because of the Novelty of this study, gaps of knowledge on SNPs affecting 
treatment response to ACS exist, which need to be filled by follow-up studies.  
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6. Summary of results 
 
It can be said the following SNPs for WOMAC rs5224 C>T (BDKRB2), 
rs7709656 G>A (GLRA1) and for VAS rs1888861 A>G (TrkA) were identified 
showing a correlation non-coincidentally with alteration in pain phenotype in 
symptomatic midstage KOA (n=272). An overlap of associated SNPs between 
baseline pain using either VAS or WOMAC was not observed. The significance 
threshold was set to p < 1.892e-5 after applying the Bonferroni correction. 
Calculations showed that presence of the minor allele T of rs5224 C>T BDKRB2 and 
A of rs7709656 G>A GLRA1 correlate with an enhanced pain perception (beta 4.6 – 
5.0) in KOA in our dataset. Consequently, presence of these two minor alleles are 
protective alleles against suffering from painful KOA. The presence of the minor 
allele G of rs1888861 A>G TrkA is associated with a decrement in pain report with an 
effect size of -5.2 < beta > -5.0. 
Results from regression tests show that the covariates previous history and 
age do not confound the association between the three SNPs -acting as independent 
variables- and pain perception –the dependent variable- in KOA in our dataset 
(n=272). Same SNPs frequently correlate (9.86e-05 < p > 4.99e-04) with pain report in 
absence as well as in presence of covariates applied separately and in combination.  
Consequently, an enhanced estimation of pain perception through these 
covariates cannot be given since the most significant SNPs do not alter under 
various application of covariates.  
 When BMI was applied as a sole covariate regression analysis found SNP 
rs3780446 G>A GABBR2 (p = 0.001653) to correlate with a decrement of pain 
report. Rs3780446 G>A being the most significant SNP out of the regression test did 
not appear to correlate with pain report in tests including other covariates, keeping in 
mind, that this SNP is markedly below the significance threshold of p < 1.892e-5. Test 
results showed that rs1888861 A>G (TrkA) was not associated with pain report under 
application of BMI as a sole covariate, as it did with the other covariates age and 
previous surgery.  
 Q/Q-plots and the genomic inflation factor, lambda, proposed no systemic 
deviation, signifying an absence of population stratification, for all regression 
analyses carried out.  
Moreover, a different set of SNPs including rs502434 G>A GRIA3 and 
rs3782025 T>C HRT3B (when phenotypic WOMAC was used) were singled out 
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through regression analysis to have an impact (7.55e-05 < p > 2.56e-04) upon 
treatment response under ACS, see table 17. When comparing these index SNPs of 
pain perception and treatment response to ACS, an overlap –which could be 
explained through this data- was ruled out. SNPs for pain report differed from SNPs 
involved in treatment response.  
A link between 3 SNPs - rs17689135 G>T VPS4B (under WOMAC), 
rs10011589 T>A GRIA2 (under WOMAC) and rs6490121 A>G NOS1 (under VAS)- 
and treatment response to HA was detected within our dataset (0.00052 < p > 
0.00096). Significance of the association does not pass the threshold of p < 1.892e-5.  
 In regression analysis for treatment response to PL one single SNP rs6698337 
G>A INADL under application of the phenotypic WOMAC data was found to be 
associated (p = 0.00073), however not passing the Bonferroni threshold, with an 
increased response to saline injection. 
 Both Null-Hypotheses22 for SNP-dependent alteration in pain report and 
treatment response in symptomatic KOA patients can be discarded and Hypothesis 1 
and 2 about a non-coincidental association between SNPs and pain report and 
treatment response respectively can be accepted.  
 
  
                                                 
22 Null-Hypotheses state that a link between SNPs and pain report and treatment response 
respectively does not exist.  
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Appendix 
 
Annex I: Abbreviations  
3’UTR three prime untranslated region 
5’UTR five prime untranslated region 
AAOS American Academy of Orthopedic Surgeons 
ACS autologous conditioned serum 
ADAMTS disintegrin and metalloproteinase with thrombospondin motifs 
AMPA alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid, glutamate 
receptor  
ARE AU-rich element  
BDKRB2 bradykinin receptor B2 
BDNF brain-derived neurotrophic factor  
BK bradykinin 
BMI body-mass-index 
Bp base pair  
CAT catalase  
CCP cyclic citrullinated peptide 
CEU Western European ancestry  
cGMP cyclic guanosine monophosphate 
Chr chromosome 
CNR1 cannabinoid receptor 1  
COMT Catechol-O-Methyltransferase 
COX2 cyclooxygenase 2 
cPLA2 cytosolic phospholipase A2 
CPN1 carboxypeptidase N subunit 1 
CRHR1 corticotropin releasing hormone receptor 1  
CRP c-reactive protein 
DIPJ distal interphalangeal joint 
DNA deoxyribonucleic acid  
EGFR epidermal growth factor receptor  
eQTL expression quantitative trait locus 
ERK extracellular signal-regulated kinase 
ESR2 estrogen receptor 2 
FDA food and drug administration 
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GABBR2 GABA (gamma aminobutyric acid) receptor B2  
GABRA4 gamma-aminobutyric acid type A receptor alpha 4 subunit  
GDP guanosine bbisphosphateGLRA1 glycine receptor alpha 1 
GNB guanine nucleotide-binding protein (G-protein) 
GPA global patient assessment of treatment efficacy 
GPCR g protein-coupled receptor 
GRIA2 ionotropic glutamate receptor AMPA type subunit 2 
GRIA3 ionotropic glutamate receptor AMPA type subunit 3 
GTP guanosine triphosphate 
GWAS genome wide association studies 
HA hyaluronic acid 
HIV human immunodeficiency virus 
HTR3B 5-hydroxytryptamine receptor 3B  
HWE Hardy-Weinberg-Equilibrium 
i.v. intravenous  
IBS irritable bowel syndrome  
IL interleukin 
IL-1Ra Interleukin-1 receptor antagonist 
IL-1Ra interleukin-1-receptorantagonist 
IL10 interleukin 10 
INADL alias PATJ, crumbs cell polarity complex component  
JNK c-Jun N-terminal kinase 
JSN joint space narrowing 
KOA knee osteo arthritis 
KOA knee osteoarthritis 
LD linkage disequilibrium 
MAF minor allele frequency 
MAOA monoamine oxidase A  
MAPK1 mitogen-activated protein kinase 1 
MEK mitogen-activated protein kinase kinase 
miRNA microRNA 
MMP matrix metalloproteinase 
MRE microRNA response element 
mRNA messengerRNA 
NGF nerve growth factor 
NMDA N-methyl-D-aspartate 
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NOS1 nitric oxide synthase 1 
NOS3 nitric oxide synthase 3  
NRG1 neuregulin 1 
NSAID nonsteroidal anti-inflammatory drug 
NT neurotrophin 
OA osteoarthritis 
OARSI Osteoarthritis Research Society International 
OPRM1 opioid receptor mu 1  
p.o. per os 
PACE4 paired amino acid converting enzyme 4 
PCSK6 proprotein convertase subtilisin/kexin type 6 
PGE prostaglandin E 
PGI prostaglandine 1 
PKA protein kinase A 
PKC protein kinase C 
PKG protein kinase G 
PL placebo 
PNOC prepronociceptin 
PRKCE protein kinase C epsilon  
PRP platelet rich plasma 
PTGS1 prostaglandin-endoperoxide synthase 1  
Q/Q-plot Quantile-Quantile-plot 
Raf kinase of three serine/threonine-specific protein kinase 
Ras a small GTPase 
RCT randomized control trials 
RNA ribonucleic acid  
RoM range of movement 
SCN9A sodium voltage-gated channel alpha subunit 9 
SF-8 HRQL Short-Form 8 health-related quality of life survey  
sGC soluble guanylyl cyclase 
SLC6A3 solute carrier family 6 member 3 
SNP single nucleotide polymorphism 
STAU1 staufen double-stranded RNA binding protein 1 
TF transcription factor 
TMD temporo-mandibular joint disease 
TNF tumor necrosis factor  
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TrkA tropomyosin receptor kinase A 
TRP transient receptor potential cation channel  
TRPA1 transient receptor potential cation channel, subfamily A, member 1 
TRPM8 transient receptor potential cation channel, subfamily M, member 8 
TRPV1 transient receptor potential cation channel, subfamily V, member 1 
UNC University of North Carolina 
VAS visual analog scale  
VEGF vascular endothelial growth factor 
VPS4B vascular protein sorting 4 homolog B  
WHO World Health Organization 
WOMAC western Ontario and McMaster Universities Arthritis Index 
 
Annex II: Labels of tables 
Table 1: Kellgren-Lawrence-Classification 
Table 2: Display of baseline characteristics of patients of Baltzer study  
Table 3: Comparison of Womac and VAS in subgroups ACS, HA and PL at different 
time points  
Table 4: Regression analysis with all covariates 
Table 5: Regression analysis with age as a covariate 
Table 6: Regression analysis with history of previous surgery 
Table 7: Regression analysis with BMI  
Table 8: Regression analysis without covariates 
Table 9: Information to SNPs found to be associated with altered pain perception 
Table 10: Lambda 
Table 11: Possible association between SNPs in pain report and treatment response 
to ACS 
Table 12: Regression analysis for treatment response to ACS 
Table 13: Comparison of most significant SNPs in ACS with HA and PL 
Table 14: Regression analysis for treatment response to HA 
Table 15: Regression analysis for treatment response to PL 
Table 16: Association between SNPs and pain report  
Table 17: Association between SNPs and altered treatment response to ACS 
Table 18: Association between SNPs and altered treatment response to HA 
Table 19: Association between SNPs and altered treatment response to PL 
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Table 20: Consequence of a SNP 
Table 21: Information about SNP found in treatment response to ACS 
Table 22: Genotype frequencies for SNPs in Hypothesis 1 
 
Annex III: Labels of figures 
Figure 1: Flowchart  
Figure 2: Example of Q/Q-plot 
Figure 3: Example of Manhattan plot 
Figure 4: Example of LD-plot 
Figure 5: Example of LocusZoom 
Figure 6: Q/Q-plots of reg. analysis with all covariates 
Figure 7: Q/Q-plots of reg. analysis with age as covariate 
Figure 8: Q/Q-plots of reg. analysis with preop as covariate 
Figure 9: Q/Q-plot of reg. analysis with BMI as covariate 
Figure 10: Q/Q-plots of reg. analysis without covariates 
Figure 11: Manhattan plots of reg. analysis without covariates 
Figure 12: LD for replication of data 
Figure 13: Q/Q-plots for treatment response to ACS 
Figure 14: Q/Q-plots for treatment response to HA 
Figure 15: Q/Q-plots for treatment response to PL  
Figure 16: Possible effects of a SNP depending on its location 
Figure 17: GTex boxplots: SNPs effect on gene expression 
Figure 18: Pathway analysis for TrkA  
Figure 19: Pathway analysis for TrkA  
Figure 20: Pathway analysis for BDKRB2 
Figure 21: Pathway analysis for GABBR2 
Figure 22: Pathway analysis for GPCR  
Figure 23: Interaction between TrkA, BDKRB2 and TRPV1 
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Annex IV: WOMAC  
The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) 
Name:____________________________________________ 
Date:________________  
Instructions: Please rate the activities in each category according to the following 
scale of difficulty:  
 
0 = None, 1 = Slight, 2 = Moderate, 3 = Very, 4 = Extremely  
 
Circle one number for each activity 
  
Pain  
1. Walking 0 1 2 3 4  
2. Stair Climbing 0 1 2 3 4  
3. Nocturnal 0 1 2 3 4  
4. Rest 0 1 2 3 4  
5. Weight bearing 0 1 2 3 4  
 
Stiffness  
1. Morning stiffness 0 1 2 3 4 
2. Stiffness occurring later in the day 0 1 2 3 4  
 
Physical Function  
1. Descending stairs 0 1 2 3 4  
2. Ascending stairs 0 1 2 3 4  
3. Rising from sitting 0 1 2 3 4  
4. Standing 0 1 2 3 4  
5. Bending to floor 0 1 2 3 4  
6. Walking on flat surface 0 1 2 3 4  
7. Getting in / out of car 0 1 2 3 4  
8. Going shopping 0 1 2 3 4  
9. Putting on socks 0 1 2 3 4  
10. Lying in bed 0 1 2 3 4  
11. Taking off socks 0 1 2 3 4  
12. Rising from bed 0 1 2 3 4  
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13. Getting in/out of bath 0 1 2 3 4  
14. Sitting 0 1 2 3 4  
15. Getting on/off toilet 0 1 2 3 4  
16. Heavy domestic duties 0 1 2 3 4  
17. Light domestic duties 0 1 2 3 4  
Total Score: ______ / 96 = _______%  
 
Comments / Interpretation (to be completed by therapist only): 
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Annex V: Ethics Votum  
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